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Bacillus Calmette-Guerin (BCG) is the first line therapy for bladder cancer 
patients with non-invasive disease. However, roughly 40% of patients exhibit no 
response, tumor recurrence or tumor progression following BCG treatment. Type 
I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma 
(UC) and may be an alternative treatment option for patients who do not respond 
to BCG standard of care. However, the mechanisms that mediate the IFN-I-
stimulated immune responses against UC are not fully elucidated. Herein, we 
evaluated the anti-tumor mechanisms of IFN-I in UC by use of adenoviral 
interferon-α (Ad-IFNα/Syn3) in human patients, and poly(I:C) or lentiviral IFN 
(LV-IFN) in mice. To this end, I evaluated the IFN-I enhanced immune response 
by observing increases in expression of immune cell and checkpoint markers in 
tumors pre- and post- IFN-I treatment. I also characterized the tumor-immune 
landscape, identified important antitumor effector cells, and described the 
pathways elicited to recruit the immune response. I found that IFN-I increased 
the intratumoral levels of Ly6G cells, CD8 T cells, and NK cells, and that the anti-
tumor benefit of IFN-I was dependent on IL-6 signaling and multiple immune cell 
types. I sought to establish therapeutic synergy between IFN-I therapy and PD-1 
pathway checkpoint inhibition, and found combination therapy increases survival 
but is not wholly synergistic, and has additional effect in increasing the immune 
infiltrate, angiogenesis, and enriching gene signatures of metabolism, 
extracellular matrix organization, and MAPK/AKT signaling. Altogether, these 
studies highlight the importance of targeting multiple aspects of the immune 
response against tumors, and provide a preclinical conceptual example for using 
type I IFN activation to increase the therapeutic benefit of PD-1 blockade for 
bladder cancer patients. 
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Chapter 1: Introduction 
The term “cancer” was first described by Hippocrates in the late centuries Before 
Common Era, but incidences of cancerous lesions have been documented back 
to the Ancient Egyptians. Hailing to the treatment practices of those archaic 
times, surgical intervention and removal of tumors has been the ultimate method 
of therapy for cancer since 1500 B.C.E. (1). The surgery itself could be 
dramatically aggressive, resulting in loss of life, low life expectancy, and low 
quality of life, if preserved. Not until the early 20th century did other treatment 
modalities such as radiation and hormone therapy begin to enter the medical 
field, with indications for the treatment of cancers, particularly for tumors 
incapable of being safely resected by surgery.  The premise of chemotherapy 
was introduced by coincidence during World War II, a by-product of defense 
research to protect soldiers against mustard gas. Since its discovery, 
chemotherapy has been catapulted into the front line of cancer treatments; 
agents which first began as general DNA damagers have evolved into pathway- 
and gene-specific targeted drugs that can be used alone, in combination with 
other chemotherapy agents, or used in an adjuvant capacity in combination with 
other therapy modalities. The most recent addition to the arsenal of cancer 
therapeutics has been the rapidly expanding field of immunotherapy. With the 
goal of capitalizing on the body’s own defense system, immunotherapy has been 
highlighted as the future of cancer therapy, meant to succeed where most other 
modalities have failed in treatment and prevention of recurrence. In the following 
chapter, I aim to provide an overview of the current field of bladder cancer and its 
diagnosis and treatment, our immune system and how it recognizes and respond 
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to tumors, with attention paid to mechanisms of tumor-immune suppression, and 
finally a discussion on the immunotherapies used to overcome tumor-
immunosuppression and treat cancer, focusing on the current status of therapies 
in all tumors and specifically in bladder cancer. 
 
1.1: Bladder Cancer 
 
Bladder cancer is the second most widely prevalent cancer type of the 
genitourinary malignancies, ranking as the tenth most common malignant 
disease worldwide (2). Indeed, 80,470 new cases of bladder cancer and 17,670 
estimated deaths attributed to bladder cancer were predicted to occur in the U.S. 
in 2019 (3), making it the fourth most common cancer type in men and the twelfth 
most common type in females. These estimated incidence and death rates have 
increased by 4.4% and 7.3%, respectively, since 2016. Bladder cancer affects 
men more frequently than women at a ratio of about 3:1, and incidences increase 
with age (2). While genetic predisposition to bladder cancer and other 
environmental factors related to diet and occupational exposure to chemical and 
water contaminants have shown to be linked to bladder cancer diagnoses (4), 
cigarette smoking is the primary risk factor for bladder cancer. Unsurprisingly 
epidemiologically, regions where smoking rates are highest have the highest 
rates of bladder cancer occurrence.   
Most patients are initially diagnosed due to observance of blood in their 
urine (hematuria)(5), subsequently confirming the presence of suspected 
cancerous lesions by cystoscopy, biopsy, and histopathology. As with most 
cancer types, prognosis for bladder cancer depends on the stage and 
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histopathology of the disease. Early staged, minimally-invasive tumors generally 
present with good prognosis following the standard of care of tumor resection, 
Bacillus Calmette-Guerin (BCG) therapy, and lifelong monitoring (6); patients 
with late staged, advanced and potentially metastatic disease have little 
treatment options as alternative to aggressive chemotherapy and cystectomy, or 
surgical removal of the bladder (7). Despite having a good prognosis, patients 
still have high rates of disease recurrence and even progression, making bladder 
cancer one of the most expensive of all cancer types due to the constant 
surveillance and need for reception procedures. For the more aggressive and 
muscle-invasive cancers, radical cystectomy, including prostatectomy in men and 
hysterectomy in women in addition to bladder removal, is the gold-standard of 
therapy. These procedures result in severely impaired quality of life and an 
abysmal 10-year survival rate of <34% when disease involves the surrounding 
lymph nodes (8).  With a fairly stable bladder cancer incidence due to the lasting 
effects of global tobacco usage, and the potential of costly life-long monitoring 
and lowered quality of life, there is great interest in development of effective 
alternative treatment options to improve the care and survival of bladder cancer 
patients. 
This section aims to provide a discussion of key differences in bladder 
cancer phenotypes, Muscle-Invasive bladder cancer (MIBC) and Non-muscle 
Invasive bladder cancer (NMIBC) with a focus on NMIBC, and provide a 
summary of the current treatment practices and the utility of biomarkers in early 
detection and therapy response. 
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1.1.1: Defining the Characteristics of Muscle-Invasive vs. Non-Muscle Invasive 
Bladder Cancer Phenotypes 
 
Pathophysiology. Most incidences (about 90%) of bladder cancer are classified 
as urothelial carcinomas, and originate from the epithelial cells lining of the 
bladder called the urothelium (5). Tumors differ greatly in their histology owing to 
their diverse cells of origin or to divergence of cell clones (clonality), which results 
in multifocal disease within the standard two-pathway development model of 
bladder cancer (papillary, non-invasive lesions or non-papillary, invasive lesions). 
Bladder cancer is staged according to the classical Tumor, Node, Metastasis 
(TNM) system in which minimally invasive tumors (stages Tis, Ta, and T1) 
represent tumors that have remained on the urothelial mucosal surface, 
potentially beginning to invade the submucosal lamina propria, or carcinoma in 
situ (CIS) (Figure 1). These tumors may also characteristically project out into 
the bladder lumen, becoming papillary in nature. Tumors can additionally be 
classified as low-grade or high-grade depending on their invasive status into the 
lamina propria and muscularis propria. Stage T2, T3, and T4 tumors have 
invaded past the first two tissue layers (urothelium and lamina propria) into the 
muscular bladder wall and beyond. Early staged tumors (Tis-T1/T2) are typically 
classified as non-muscle invasive bladder cancers (NMIBC), and late stage 
tumors (T2-T4) are usually appropriately named muscle-invasive bladder cancers 
(MIBC) (5, 9). Approximately 75% of new diagnoses of bladder cancer are 
NMIBC, and the other 25% of cases are MIBC or metastatic disease (4). About 
15-40% of high-grade Ta staged NMIBC tumors, and 30-50% of high-grade T1 
staged NMIBC tumors progress to highly invasive disease; however only about 
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20% of initially diagnoses NMIBC patients progress to MIBC with the potential for 
metastasis (10). Urothelial carcinomas can also be classified by variant 
Figure 1: Stages, grades, and subtypes of bladder cancer. Staging of bladder 
cancer according to the TMN system is shown according to the tissue layer of the 
tumor invasion. Non-muscle invasive (NMIBC) tumors are the least tissue 
invasive tumors, typically papillary in nature and have lower stages (Tis-T1/T2) 
and lower graded disease. Muscle-invasive (MIBC) tumors are more aggressive 
with higher stages (T2-T4) and higher grades, including invasion past the bladder 
muscular wall and into fat and the bloodstream. Grading schemes at the bottom 
of the figure reflect World Health Organization (WHO) and International Society 
of Urological Pathology (ISUP) disease stratification classifications. PUNLMP, 
papillary urothelial malignancy of low malignant potential. This figure was taken 
with permission from Sanli, O, Dobruch J, Knowles MA, Burger M, Alemozaffar 
M, Nielsen ME, Lotan Y. 2017. Bladder Cancer. Nat Rev Dis Primers (5). License 
number 4580430584829. 
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histologies including micropapillary, sarcomatoid, squamous, and glandular 
differentiation (11); many of these subtypes are aggressive and thus important to 
identify in order to avoid misdiagnoses and inappropriate treatment regimes.  
 
Molecular Characteristics. In addition to the TNM classification and invasion 
status, bladder tumors can be subtyped by their molecular landscape and 
characteristics. In humans and also in mouse models of NMIBC, precursors to 
tumors present as hyperplastic lesions where the two most common genetic 
alternations found are loss of heterozygosity of chromosome 9, particularly 9q, 
and mutations in FGFR3 (12, 13). The deleted areas on chromosome 9 
encompass loci for multiple tumor suppressors including CDKN2A, TSC1, and 
PTCH1, and are often found deleted in other tumor types (14, 15). FGFR3 
activating mutations can trigger activating mutations in PIK3CA and downstream 
cell cycle regulatory pathways such as RAS/MAPK signaling, resulting in 
increased cell growth and division (15, 16). Whole exome-sequencing of NMIBCs 
revealed high frequencies of inactivating mutations in chromatin-modifying 
proteins KDM6A, ARID1A, CREBBP, and EP300, present at significantly higher 
levels than in other cancer types, signifying a key role for epigenetic regulation in 
the development of these tumors (17-19). In contrast to NMIBC, flat dysplastic 
lesions or CIS are precursors to MIBC tumors, with generation of MIBCs in 
humans and mouse models requiring the inactivation of tumor suppressor genes 
Trp53, Rb1, and Pten. These alterations affect cell cycle regulation, genetic 
instability and immortality, and regulation of the PI3K/AKT/mTOR pathway (20), 
ultimately resulting in increased disease aggressiveness, invasion, and worse 
clinical outcomes. In addition to the difference in overall patterns of mutated 
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genes in these two major tumor groups, there is also a significant difference in 
their mutational burden. According to exome sequencing studies, NMIBCs have 
showed an average of 169-195 mutations, less than two-thirds of 302 mutations 
found in MIBCs (17, 18).  
 
Molecular Subtyping. Molecular subtyping of bladder cancer goes deeper than 
just characteristics identifying NMIBC and MIBC.  As briefly touched on above, 
urothelial carcinoma can have differing cells of origin, generating heterogeneous 
tumors with varying clinical outcome suggesting there can be subtyping within 
subtypes. Transcriptional profiling has provided the best subtyping definitions, 
though to date, the major studies performed use different nomenclatures and so 
bioinformatics tools have been enlisted to find alignment and overlap of these 
profiles (Figure 2). The initial profiling study performed by Lund encompasses 
tumors of all grades and stages (NMIBC and MIBC) and defined the following 
five subtypes: urobasal A, genomically unstable, (immune) infiltrated, squamous 
cell carcinoma-like, and urobasal B (21). Low-grade Ta tumors were classified as 
urobasal A, consisting of high levels of markers of urothelial differentiation, cell 
adhesion, early cell cycle, and FGFR3-related genes. Stage T1 and high-grade 
tumors contained more genomically unstable and infiltrated tumors, classified by 
late cell cycle gene expression and markers of urothelial differential, or high 
levels of immune cell and stromal markers, respectively. These higher-staged 
NMIBC tumors showed more overlap with subtypes of MIBC, which other 
independent transcriptional analyses have segregated into two major tumor 
groups: “luminal” and “basal” (18, 22, 23). The luminal and basal clusters are 
identified by mutually exclusive expression of differentiation markers that were 
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Figure 2: Molecular subtyping of bladder cancer. Several subtypes of NMIBC 
and MIBC have been defined based on transcriptional characteristics. a) 
UROMOL classification scheme of NMIBC into three class subtypes: Class 1 is 
characterized by high expression of early cell cycle and uroplakin genes, which 
are involved in urothelial differentiation; Class 2 expresses late cell cycle genes 
and shows increases in keratins as well as uroplakins; Class 3 tumors show high 
expression of keratins, a sign of undifferentiated (basal) cells, and high levels of 
long non-coding RNAs. b) Characterization of bladder cancer subtypes defined 
by the University of North Carolina (UNC), MD Anderson Cancer Center (MDA), 
The Cancer Genome Atlas (TCGA), and Lund University (Lund) projects. UNC, 
MDA, and TCGA included MIBC alone; Lund included both NMIBC and MIBC. 
Key markers and therapeutic targets are shown aligning to Lund nomenclature. 
This figure was taken with permission from Sanli, O, Dobruch J, Knowles 
MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. 2017. Bladder Cancer. Nat 
Rev Dis Primers (5). License number 4580430584829.  
 9 
similar to the intrinsic basal and luminal subtypes of breast cancer (24). MIBC 
luminal tumors often display papillary morphology and express markers of 
urothelial differentiation such as KRT20, uroplakins, E-cadherin, early cell cycle 
genes, and FGFR3. Basal tumor markers reflect their cells of origin in the basal 
layer of the bladder, expressing CD44, KRT5, KRT14, markers of EMT, with 
some showing low expression of the claudin gene family or squamous 
differentiation markers (25). Data from studies performed by UNC, MD Anderson, 
and TCGA show that their MIBC clusters overlap with the Lund study’s subtyping 
nomenclature of unstable and infiltrated tumors (mostly luminal MIBC), and the 
more basal-like groups of urobasal B and squamous cell carcinoma-like (basal 
MIBC) (21).  
Of the major currently published transcriptional studies, the UROMOL 
study focused solely on NMIBC, transcriptional profiling 460 patients with either 
low-grade or high-grade Ta, T1 and CIS tumors (26).  Comparing their 
nomenclature to the original Lund findings, UROMOL Class 1 tumors were very 
similar to urobasal A tumors. Consisting of mostly Ta tumors, patients who were 
Class 1 showed the best prognosis of all groups. Class 2 contained more high-
grade and T1 tumors, more likely to be at risk for recurrence and progression to 
MIBC, and aligned most commonly with genomically unstable and infiltrated Lund 
profiles (21). It is thought that Class 2 tumors, may represent tumors of origin for 
luminal-like MIBC tumors that retain more markers of urothelial differentiation, 
based on their characteristic expression of late cell cycle, EMT, and stem-cell 
related genes (5). Class 3 tumors had both common gene signatures like FGFR3 
of the urobasal A subtype, but also displayed a basal expression pattern similar 
to basal MIBCs including expression of KRT5+, KRT14+, and CD44+ (26).  
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Some researchers in the field believe that molecular subtyping of bladder 
cancer is at the forefront in the future of disease diagnostics and treatment 
planning, predicting that the use of transcriptional profiling will overtake the 
traditional reliance on pathology for bladder cancer diagnosis. However, despite 
the broader categories of luminal and basal and even more defined categories 
like infiltrated and genomically unstable, within each subtype are more specific 
tumors types with actionable therapeutic targets, suggesting that future 
dependence on molecular classifiers for cancer diagnosis could be a journey 
down the rabbit hole. This prospect it a heavily debated topic among the field, 
and for the immediate future, efforts are aimed at combining conventional 
histopathology, immunohistochemistry, and molecular classification to subtype 
bladder cancer diseases and assign therapy (27-30).  
In summary, bladder cancer is broadly assigned to a two-pathway system: 
non-muscle invasive (NMIBC) or muscle-invasive (MIBC). These two 
classifications differ in their stage and grade, as well as their molecular 
landscapes and molecular subtypes.  These characteristics influence disease 
pathology, progression, and prognosis. NMIBCs tend to be papillary, earlier 
staged, lower grade, and minimally invasive, characterized by FGFR3 mutations 
and higher expression of urothelial differentiation markers, but overall lower 
mutational burden. MIBC tumors by comparison are more dysplastic, aggressive, 
higher staged, and potentially metastatic. They are characterized by TP53, RB1, 
PTEN, and PI3K/AKT/mTOR pathway mutations, have higher mutational loads, 
and can be broadly molecularly subtyped into luminal and basal MIBC.  The 
differences in these two urothelial tumor classifications lead to significant 
variation in clinical implications, as well as treatment and disease management. 
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In the future, there needs to be a consensus on nomenclature and characteristics 
of bladder cancer subtypes to aid in standardization of patient diagnoses and 
development of comprehensive treatments (31). The studies described in the 
subsequent chapters will be focused on NMIBC disease. 
 
1.1.2: Standard Treatment Practices for Urothelial Carcinomas 
 
Diagnosis and prognosis. As previously mentioned, most bladder cancer 
patients are diagnosed due to incidence of hematuria that is followed by 
evaluation by cystoscopy (32). Abnormal findings potentially indicating papillary, 
solid, muscle-invasive, or carcinoma in situ lesions require histological 
confirmation obtained from biopsy or transurethral resection of the tumor area 
(33). Commonly, urine cytology is measured in conjunction with cystoscopy to 
detect missed cancer: shed abnormal cells can indicate the presence of 
cancerous lesions (34). Expectedly, bladder cancer prognosis and disease 
management depend on classification of either NMIBC or MIBC lesions, staging, 
and grading (7, 35, 36). In low grade NMIBC tumors (Ta, T1), recurrence is 
usually common, but with low risk of progression; in high grade NMIBC tumors 
(majority T1, CIS), often regarded as precursors to development of invasive 
cancer, progression rates range from 40-83% if tumors are left untreated (37). 
MIBC tumors (T2, T3, T4), even after aggressive chemotherapy and radical 
cystectomy have recurrence rates of 20-30% for T2, 40% for T3, and >50% for 
T4 staged lesions (38). These patients also have shown a 5-year overall survival 
rate of less than 30% (39); additionally of note, initially diagnosed NMIBCs that 
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have progressed to MIBC show worse overall prognosis and cancer-specific 
survival as compared to primary diagnosed MIBC (40). 
 
Management and treatment. All newly diagnosed bladder tumors undergo 
endoscopic resection, typically as part of diagnostic cystoscopy. This procedure, 
transurethral resection of bladder tumor (TURBT), is performed to remove all 
visible tumor and provide an appropriate sample for accurate pathologic staging 
(33). Multiple guidelines are available for recommended management of bladder 
cancer, but in general, NMIBCs are typically managed by TURBT and risk-based 
intravesical therapy with Bacillus Calmette-Guerin (BCG), while MIBCs are more 
insistently treated with radical surgery with or without pre-surgical systemic 
therapy of chemotherapy, radiation, or immunotherapy (7, 35, 41, 42).  
TURBT. TURBT is performed by passing an electrified-wire loop resectoscope 
through the urethra during local or general anesthesia, resecting the tumor in a 
piecemeal fashion until all visible tumor is removed (43). Patients with low-risk 
disease, identified by solitary, Ta tumors that are <3 cm in size, are often treated 
by an initial TURBT followed by routine surveillance by cystoscopy for up to 5 
years, with future recurrences treated with additional TURBT (42). Intermediate- 
and high-risk patients, identified by larger, multifocal or recurrent Ta tumors, T1 
tumors, or CIS, follow initial TURBT with lifelong surveillance, potential repeat 
TURBT, and adjuvant immunotherapy with intravesical BCG (42). Unfortunately, 
understaging disease is a serious risk for patients, caused by incomplete 
resection due to tumor multiplicity, size or location, and results in inadequate 
treatment and higher probability of disease relapse and progression (44, 45). 
Thus, it is important and recommended for high-grade disease to be resected 
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again when incomplete resections have occurred, or when the tumor invades 
past the urothelium, to improve staging accuracy and patient survival (46, 47). 
Traditional TURBT as treatment for more advanced disease is not highly 
practiced due to chance of bladder perforation and the inevitable decision for 
removal of the bladder (48). 
Intravesical therapy. Bladder cancer patients with intermediate- and high-risk 
NMIBC disease typically undergo adjuvant intravesical therapy with BCG. BCG, 
or Bacillus Calmette-Guerin, is an attenuated mycobacterium originally 
developed as a vaccine for tuberculosis (49). It was found to provide antitumor 
activity in urothelial carcinoma by intravesical instillation into the bladder by 
decreasing recurrence and inhibiting tumor progression (50). BCG acts as an 
immunotherapy, in that it stimulates a local inflammatory response characterized 
by an influx of granulocytes, monocytes and dendritic cells, and induced 
expression of inflammatory cytokines such as TNF-, GM-CSF, IFN, IL-2 among 
others (51). This inflammatory response is believed to activate a cytotoxic cell-
mediated killing of tumor cells, producing the efficacy of BCG in preventing 
recurrence and progression (52). In North America particularly, patients treated 
with BCG exhibited a 68% complete response rate compared to 47% of patients 
receiving chemotherapy (53). Adjuvant therapy with BCG includes maintenance 
therapy (follow up instillations after initial treatment course) for 1-3 years 
depending on disease risk to further reduce incidence of tumor progression. 
Patients who have tumor recurrence/relapse, disease progression, or have 
intolerable adverse effects while on maintenance therapy or after treatment 
course of BCG are deemed “BCG unresponsive” or “BCG failures” (54). For 
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these patients, there are few alternative therapeutic options to radical 
cystectomy, although bladder preservation strategies including chemotherapy, 
investigational immunotherapeutic agents, and clinical trials may be considered 
(55). 
Cystectomy. For patients with high grade NMIBC, BCG unresponsive NMIBC, 
and MIBC, cystectomy (surgical removal of the bladder), or radical cystectomy 
with lymph node dissection is the gold standard of treatment. Radical cystectomy 
in men includes prostatectomy, and in women includes hysterectomy, and partial 
excision of the vagina and urethra (5). Following radical cystectomy, urine is 
diverted from its normal pathway by a segment of intestine into either a newly 
constructed neobladder (intestine segment with anastomosed ureters) which can 
still provide continence, or into a non-continent ileal conduit diversion brought to 
the skin as a stoma for use with an urostomy bag (56). Survival outcomes post-
radical cystectomy depend on final pathological staging of the removed bladder 
and tumor. The 10-year recurrence-free survival is 76% for patients staged T1-
T3a, 61% for T3b, and 45% for T4 when lymph nodes are not involved in cancer 
progression/stage, but when lymph nodes are involved survival drops to 34% 
regardless of stage (8). Radical cystectomy can seriously affect patient quality of 
life, and so much effort is being put towards perioperative care and Enhanced 
Recovery after Surgery (ERAS) protocols. 
 Systemic therapy. Neoadjuvant and adjuvant chemotherapy are used mostly in 
MIBC patients both prior to and directly following radical cystectomy to varying 
results. Typically, platinum based chemotherapy is efficacious used in a 
gemcitabine-cisplatin combination, producing a decrease in risk of death after 
surgery and a reduction in diseases recurrence (57, 58). In the neoadjuvant 
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setting, arguments for cisplatin-based chemotherapy use include its potential to 
downstage bulky and invasive tumors which can improve surgical outcomes, but 
its use can also delay other therapies and allow disease progression if patients 
do not respond (11). Patients who are diagnosed with metastatic disease initially 
or following cystectomy are treated with standard of care cisplatin-based 
chemotherapy combinations such as methotrexate, vinblastine, doxorubicin, 
cisplatin (M-VAC), cisplatin, methotrexate, vinblastine (CMV), or gemcitabine-
cisplatin plus paclitaxel (59). However, most patients with metastatic disease, 
while initially responsive to systemic chemotherapy, will ultimately progress with 
a median survival of 14 months and an overall 5-year survival rate of 5-20% (60).   
Typically given in combination with chemotherapy rather than single 
modality for optimal survival improvement (61), radiation therapy or 
chemoradiation can be used in bladder preservation protocols when radical 
surgery has substantial quality of life consequences. These treatments are 
subsequent to TURBT (together deemed trimodal therapy) and can result in 5-
year cancer-specific survival rates between 50-82%, although roughly one-fourth 
of patients will eventually need to undergo radical cystectomy due to lack of 
response (62). 
Systemic immunotherapy has more recently come into treatment practices 
in MIBC with the recent US Food and Drug Administration approval of 
atezolizumab (anti-PD-L1 mAb) and nivolumab (anti-PD-1 mAb) for treatment of 
advanced and metastatic urothelial carcinoma (63). Initial results as a second-
line treatment have been promising enough that clinical trials are ongoing for 
first-line care, and patients in earlier stages of urothelial cancer. 
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Investigational therapy. Due to frequency of recurrence of NMIBC despite BCG 
induction and maintenance treatments, and the life-changing decision for 
cystectomy, new treatments are being investigated for use in BCG unresponsive 
patients. Oncolytic viruses and adenoviral-mediated interferon- (Ad-IFN2b) are 
being explored as intravesical therapies to not only target cancer cells, but also 
to stimulate the host immune system to fight tumors cells as well (64, 65).  Early 
clinical trials of Ad-IFN2b gene therapy has shown safety and efficacy with 43% 
of patients exhibiting complete response at an average of 31 months, and 35% of 
patients free of high-grade recurrence at 1 year (66, 67). Many bladder tumors 
harbor molecular alterations that are potentially druggable, such as FGFR3 or 
alterations in the PI3K-AKT and MAPK pathways, and many clinical trials are 
enrolling and investigating the therapeutic potential of targeted therapies in 
bladder carcinoma (NCT02465060, NCT03410693, NCT03047213). As 
mentioned above, systemic immunotherapy with checkpoint inhibition in 
treatment of MIBC and NMIBC is a current area of investigation. The mechanism 
and functional importance of these will be further discussed in proceeding 
sections. 
Together, once diagnosed, it is necessary for proper stratification of 
bladder cancer patients in order to receive the most effective therapy. However, 
the most effective treatment scheme may come at high cost both literally, due to 
high disease recurrence and progression rates, and figuratively, as patients can 
face serious challenges to their quality of life depending on their disease and the 
appropriate therapeutic action. For MIBC patients, standard of care radical 
cystectomy in combination with chemotherapy or immunotherapy provides the 
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best survival outcomes. For NMIBC patients, tumor resection followed by 
intravesical BCG are standard practice generating ~70% complete response 
rates; but for those that are deemed BCG unresponsive, no effective second-line 
therapy exists as an alternative to cystectomy (68-70). These patients make up a 
target population for investigational therapies that can improve prognosis, aid in 
the preservation of bladders and nullify life-altering surgical intervention.  
 
1.1.3: Potential of Biomarkers for Early Detection, Diagnosis, and Response 
 
Early detection and diagnosis. Early screening of high-risk patients as a 
potential option for early detection for bladder cancer is not a viable option owing 
to the lack of genetic markers and heredity of the disease. However, due to the 
invasiveness and cost of cystoscopy and biopsy as diagnostic tools, there is a 
strong desire among the field to identify novel, noninvasive diagnostic methods. 
Cytology is often performed in the diagnosis of urothelial carcinoma, to serve as 
a backup mechanism for detecting malignant cells originating from the bladder 
that a cystoscopy may overlook (71); within the premise of cytology lies the 
potential for urine-based tumor markers for early cancer detection and diagnosis. 
Several proteomic based tests have been approved by the FDA for diagnosis 
and surveillance, but many of these tests are below 80% sensitivity and range 
from 60-90% in specificity (72-74). Liquid biopsy detection of urinary markers by 
cell free DNA (cfDNA) have been used prognostically in identifying bladder 
cancer recurrence, progression and metastasis (75, 76). Urinary detection of 
DNA methylation status has been used for risk stratification and to differentiate 
bladder cancer patients from controls at sensitivities > 90% (77, 78). MicroRNAs 
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(miRNAs) and expression of other genes in voided urine are also being studied 
for diagnostic testing to mixed successes, with sensitivities ranging from 71-94% 
and specificity from 51-100% (72, 79). However, despite the emerging evidence 
of the utility of urine molecular diagnostic markers, currently there are no urinary 
based tumor markers that are definitively able to detect bladder tumors based on 
sensitivity and specificity (80, 81).  
 
Markers of response. Many therapies for bladder cancer, like BCG, have been 
used for decades, and yet there is still no tool to aid in stratification of patients as 
likely responders and non-responders to therapy. Kamat and colleagues describe 
a urinary cytokine based assay that could predict the likelihood of tumor 
recurrence with 85.5% accuracy based on changes in a panel of nine induced 
cytokines after BCG therapy (82). Research on urinary exosomes as a marker for 
therapeutic response has been investigated in prostate cancer, but remain to 
show convincing evidence of correlation with response (83). To date, risk 
stratification models based on clinicopathological features from biopsied 
specimens remain the most widely used tools available to predict therapeutic 
response in bladder cancer (84). Future utilization of biomarkers in the detection 
of cancer (predictive) and response to therapy (prognostic) will require validation 
to minimize false-negative results, but their potential shows great promise in 
directing the field toward improved patient care and treatment strategies.  
 
1.1.4: Summary 
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Bladder cancer is a malignancy most often associated with older men, with a 
fairly stable incidence outlook as tobacco usage and exposure has been 
ingrained in daily life worldwide. Bladder cancer can be subtyped by several 
different phenotypic and genotypic aspects, but clinical stratification is based on 
tumor invasion status into the muscular wall of the bladder (NMIBC vs. MIBC) 
and pathological grading. While the standard of treatments for NMIBC are costly, 
though effective for the majority of patients, there is room for improvement 
particularly for those who have failed BCG. Standard treatments for patients with 
MIBC greatly affect quality of life and survival outcomes, so the continued 
investigation into immunotherapy and bladder preservation strategies is crucial. 
Improving the treatment and survival of patients with bladder cancer will require 
further development of early detection tools and more effective local and targeted 
therapies moving forward. Exploring the role of the immune response to foreign 
signals and tumors, and the mechanisms tumors use to evade the host defense 
system will be reviewed in the next section. 
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1.2: The Immune Response and Tumor Immunity 
 
The human immune system as we know it today is a product of evolution, 
originating from an archaic defense mechanism which used protein receptors to 
recognize common features of dangerous pathogens (85). The first line of 
defense for animals, known as the “innate” immune system, involves fast-
responding molecules and cells that rush to the site of an infection. The innate 
response is often sufficient to contain and eliminate sources of danger to the 
host, and is therefore a very important first step in host protection. Higher 
organisms later developed a secondary immune response, a predominantly 
cellular mechanism intricately designed to target pathogens based on specificity, 
and be able to mount a quicker defense response in the incidence of recurrent 
infection, otherwise known as “adaptive” immune memory. Although 
evolutionarily created to identify and fend off invasion and infection by 
microorganisms, the same principles of recognizing a “foreign” molecule that 
initiates a cellular and molecular immune response can be applied to cancer.  
Cancer is known for its loss of normal cell regulatory function and gain of 
innumerable genetic alterations (86). These alterations and dis-regulations have 
been known to result in the expression of antigens, leading to presentation of 
“foreign” peptides recognized by MHC molecules on surveilling immune cells 
(87). In a normal immune response, this peptide presentation and recognition by 
an immune cell would result in elimination of the tumor cell. Unfortunately, 
despite the ability of our inherent defense system to recognize and kill cancer 
cells, the durability and persistence of tumors presumably meant that something 
was hindering our immune cells from destroying it. Definitive proof of these 
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immune inhibitory mechanisms was found in mice, when Dunn and colleagues 
discovered that cancer cells had the unique ability to delete T cell targets and 
thus avoid being detected and attacked (88). Tumors can also suppress an 
immune response by activating negative regulatory pathways that exploit 
immune homeostasis and inhibit immune cell effector functions (89, 90). Deemed 
tumor-immune “evasion” or “escape”, these mechanisms allow tumors to survive 
in an environment that would normally prove hostile. 
The following section provides a background on the normal mechanisms 
of immune response when foreign antigens are discovered, including responses 
of the innate and adaptive arms of the immune system, and will also provide a 
discussion on the specialties of tumor-immunology and the mechanisms of 
tumor-immunosuppression. 
 
1.2.1: Overview of Innate vs. Adaptive Immune Response to Foreign or Tumor 
Signals  
 
Innate response. As touched on above, the innate immune system biologically 
evolved as the first line of defense against pathogens. Innate immunity usually 
encompasses the myeloid derived lineage of phagocytic and inflammatory white 
blood cells (neutrophils, monocytes, macrophages), complement, cytokines, and 
acute phase proteins, all of which are designed to provide immediate response to 
signals of infection or damage (91). These responses are hard-wired from 
germline encoded genes to recognize molecular patterns common to microbial, 
toxic, or allergenic structures that are not present in the host (92). Membrane-
associated proteins called pattern-recognition receptors (PRRs) recognize 
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essential microbial components known as pathogen associated molecular 
patterns (PAMPs) and host tissue distress signals known as damage-associated 
molecular patterns (DAMPs) (93). PRRs are constitutively expressed on large 
numbers of cells, and once activated, initiate specific signaling pathways to 
eliminate the foreign invader (94). PRRs can be differentiated by their expression 
patterns and ultimate function, generally either classified as cytoplasmic 
receptors (NLRs, RLRs) or membrane-bound receptors (TLRs). Toll-like 
receptors (TLRs) are one class of transmembrane PRRs that have been 
evolutionarily conserved across species, existing as either extracellular or 
intracellular signaling proteins that recognize microbial lipids and nucleic acids 
(Table 1) (94). Most prominently expressed on antigen-presenting cells (APCs) 
including macrophages and dendritic cells (DCs), stimulation of receptors with 
a TLR ligand (microbial component) initiates a signaling cascade driven by 
either MyD88 or TRIF adaptor molecules, resulting in the production of pro-
inflammatory cytokines and type I interferons (IFN), respectively (95, 96). IFN 
and cytokines serve to further recruit and activate more immune cells and lead 
to pathogen destruction, to be discussed more in depth below. TLRs were 
among the first targets validated for cancer immunotherapy based on the 
clinical efficacy of BCG therapy, an agonist of TLR2 and TLR4, in patients with 
early-stage bladder cancer (97). Exploitation of TLR signaling continues to be 
explored and utilized in many cancer therapies today. 
 The other major class of PRRs, cytoplasmic receptors including RIG-I 
like receptors (RLRs), cytosolic DNA sensors, and nucleotide-binding 
oligomerization domain [NOD]- leucine-rich repeat containing receptors 
 23 
(NLRs), are associated with recognition of bacterial and viral components in 
TLR PAMP	Recognition DAMP	Recognition Location Signal	Adaptor
1
Lipoproteins,	peptidoglycans,	
lipopolysaccharides cell	surface TIRAP,	MyD88
2
Lipoproteins,	peptidoglycans,	
BCG
Heat	shock	proteins	
(HSPs),	proteoglycans cell	surface TIRAP,	MyD88
3
dsRNA,	viral	RNA,	tRNA,	
siRNA,	poly(I:C) mRNA
intracellular,	
endosomes TRIF
4
lipopolysaccharides	(LPS),	
BCG HSP60,	70;	Fibrinogen cell	surface
TRAM,	TRIF,	TIRAP,	
MyD88
5 Flagellin cell	surface MyD88
6 Lipopeptides	(mycoplasma) cell	surface TIRAP,	MyD88
7
ssRNA,	imidazoquinolines,	
guanosine	analogs ssRNA
intracellular,	
endosomes MyD88
8 ssRNA,	imidazoquinolines ssRNA
intracellular,	
endosomes MyD88
9
viral	DNA,	CpG	DNA,	CpG	
ODNs
intracellular,	
endosomes MyD88
Table	1:	Recognition	by	Toll-Like	Receptors	(TLRs)
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the cytosol (98). NLR family members can sense intracellular bacterial 
peptidoglycans, cellular stress products, microbial products, and noninfectious 
crystal particles (99). The most common family members of NLRs, NOD1 and 
NOD2 and NLRPs, form oligomers once activated to further initiate production 
of other inflammatory cytokines, active NF-kB inflammatory signaling, and 
induce the inflammasome complex which leads to the cleaving and secretion of 
IL-1 family members (100, 101). RLRs are RNA helicases that recognize 
cytosolic dsRNA and are particularly important in viral infections. Unlike TLRs, 
RLRs are expressed by most cell types. The most described RLR helicases 
are retinoic-acid-inducible protein I (RIG-I), melanoma differentiation 
associated gene 4 (MDA5), and LGP2, which when stimulated initiate a 
cascade to increase production of inflammatory cytokines and type I IFN, like 
NLRs and TLRs (98). Similarly, cytosolic DNA sensors like STING and cGAS 
detect viral and cytoplasmic DNA and initiate a type I IFN inflammatory 
response. 
Surveilling phagocytes based in common entry tissues and PRR-
expressing epithelial cells are among the first responders to foreign pathogens. 
Upon PRR recognition, they initiate an NF-kB-mediated signaling cascade of 
cytokines to stimulate inflammation within the infected tissue, causing more 
DCs, macrophages, and other innate cells to produce cytokines and 
chemokines to attract circulating leukocytes and begin the first stages of the 
cellular arm of the innate response (102). These cytokines are considered pro-
inflammatory, and are important in staging the innate defense, but once 
mounted they must also be regulated to eventually subside to prevent 
extensive tissue damage (103). Common inflammation-induced cytokines and 
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chemokines include IL-1, IL-6, IL-12, TNF, IFN, IL-4, IL-10, IL-18, CXCL8, 
CCL4, RANTES, TGF and later GM-CSF and M-CSF, with functions ranging 
from monocyte differentiation, increasing vascular permeability, further immune 
cell recruitment, lymphocyte activation, and the suppression of response (104, 
105). The early response cytokines TNF and IL-1 increase expression of cell-
adhesion molecules such as selectins and integrins to attract monocytes and 
neutrophils to the site of infection (106). Chemokines CXCL8, CCL4, and 
RANTES are chemotactic cytokines, serving to recruit neutrophils, basophils, 
monocytes, T cells and other immune cells by their sensing of these small 
molecules in a gradient fashion with highest concentrations at the source of 
infection (107). IL-4, IL-10, and TGF generally serve as anti-inflammatory 
cytokines by negatively regulating the innate response. IL-10 and TGF 
suppress DC differentiation, inhibiting their ability to activate T cells, and can 
also directly inhibit T cell functions; they negatively regulate pro-inflammatory 
cytokine production and cytotoxic cell function, and induce differentiation of 
regulatory T cells, but have a role in tissue repair (105, 108). IL-4 is initially 
produced by mast cells and is important in protecting the host during parasitic 
infection (109). IL-4 has mixed roles in the inflammatory response: its 
important in the differentiation of monocytes into DCs and B cell activation, but 
following the cellular activation of the innate response, IL-4 also induces T cell 
differentiation into Th2 type cells (110, 111). IL-12 and IL-6 have roles in 
activating lymphocytes and inducing Th1 type immune differentiation (105, 
112). TNF- and IL-1 in combination with IL-6 are also important for initiating 
the acute phase response and opsonization-mediated pathogen killing (113).  
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TLRs, RLRs, and STING sensors are the major pattern recognition 
receptors that are stimulated to signal type-I interferon (IFN-I) production. Type 
I interferons (IFN- and IFN-), induced from sensing for foreign (viral) nucleic 
acids by TLR3,4,7,9, RIG-I and MDA-5, are produced by almost all cell types; 
however the major production of IFNs-I comes from plasmacytoid DCs (pDCs) 
(114). Both IFN- and IFN- induce resistance to viral replication in all cells, 
hence the name “interferon”, through the JAK/STAT signaling cascade which 
culminate in the transcriptional regulation of many interferon-stimulated genes 
(ISGs) (115). Signaling through PI3K/AKT, NF-kB, and MAPK are also 
triggered by activation of the IFN receptor, resulting in induction in cell division, 
proliferation, differentiation, and survival (116, 117). IFNs-I exert effects on the 
immune response directly by stimulating innate cells to activate other cells, and 
indirectly through the induction in chemokines, such as CXCL9, CXCL10 and 
CXCL11 for immune cell recruitment, and the induction of cytokines important 
in regulating innate and adaptive cells (118-120). IFNs-I support the migration, 
maturation, and differentiation of monocytes into DCs thereby upregulating 
antigen presentation, as well as macrophage cytotoxicity and phagocytosis 
(121, 122). They also increase MHC class I molecule expression to enhance 
antigen recognition by antigen presenting cells (APCs; DCs and macrophages) 
and encourage DC migration, together with priming and activation of the 
adaptive immune response (123-126), to be discussed further in the next 
section.  
As touched on above, IL-6 is a very pleotropic cytokine induced by PRR 
recognition of PAMPs and DAMPs, NF-kB signaling, and IFN-I signaling from 
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immune cells, but also from fibroblasts, endothelial cells, and other cells (127).  
Like other cytokines (IL-4), IL-6 is known for both pro-inflammatory and anti-
inflammatory actions. Differences in its roles may be linked to the different 
ways IL-6 signals at the plasma membrane: 1) classical signaling involves 
membrane IL-6R binding with receptor protein gp130, but not every cell type 
has membrane-bound IL-6R, and so 2) soluble IL-6/IL-6R (sIL-6R) is utilized 
and known as IL-6 trans-signaling (128). Binding of IL-6 to IL6-R and gp130 
initiates JAK/STAT or MAPK signaling pathways, the former simultaneously 
inducing a negative feedback loop to suppress IL-6 by SOCS genes (129). IL-6 
contributes to immune defense in a pro-inflammatory role by inducing the acute 
phase response, hematopoiesis (granulopoiesis), B cell differentiation, and 
interferon-like activity (130, 131). It also promotes differentiation of CD4 T cells 
in to Th17 T cells and suppresses CD4 Treg formation, and induces CD8 
cytotoxic T cell differentiation (132-134) (Figure 3). If left unchecked, these 
pro-inflammatory responses contribute to development of chronic inflammation 
and autoimmune diseases (135, 136). Anti-inflammatory effects of IL-6 include 
a role in wound healing and liver regeneration (137), and negative regulation of 
pro-inflammatory TNF, GM-CSF, IFN, and MIP-2 cytokine production in 
acute lung inflammation (138). In relation to cancer and disease pathology, IL-
6 is a known instigator of autoimmune disease such as rheumatoid arthritis and 
colitis caused by chronic inflammation (139), and has been linked to anti-
tumorigenic and pro-tumorigenic actions with poor clinical outcomes in cancer 
patients (140). IL-6 has controversial roles in immune activation, chronic 
inflammation and cancer, but it remains a strategic bridge connecting the 
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Figure 3: IL-6 in inflammation, immune response, and pathogenesis. IL-6 is 
a pleiotropic cytokine. It induces acute phase response proteins such as CRP, 
serum amyloid A, fibrinogen and hepcidin from hepatocytes. IL-6 also plays an 
important role in adaptive immunity by stimulating B cell and T cell differentiation 
and function. IL-6 can also promote proliferation of many immune and non-
immune cells. RANKL, receptor activator of nuclear factor kB (NF-kB); VEGF, 
vascular endothelial growth factor. This figure was taken with permission from 
Tanaka T, Narazaki M, Kishimoto T. 2015. IL-6 in inflammation, immunity, and 
disease. Cold Spring Harbor Perspectives in Biology (136). License number  
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innate and adaptive immune responses.     
Natural Killer cells (NK cells) serve as a special component of the innate 
immune system. NK cells have similarities to both innate and adaptive cells: they 
develop from the same progenitor cells as B and T cells, and have the ability to 
kills cells by direct contact after binding cell-surface receptors, however, NK cells 
are fast-responding and have invariant, germline-encoded receptors that 
recognize molecules on infected cell surfaces, and as such are considered innate 
cells (141). NK cells are activated in response to the triggering of their activation 
receptors by cognate ligands (142), IFNs-I, and cytokines produced from 
macrophages and DCs. Once activated, they then identify infected cells based 
on aberrations or loss of MHC class I expression, and directly kill cells by 
cytotoxic granule release (perforin) or production of IFN (143-145). Normal class 
I MHC expression is an inhibitory signal to NK cells, as this is the sign of self-host 
cells (146, 147). Loss of this inhibitory signal (normal class I MHC) was proved to 
be insufficient for NK cell killing, and that an additional activating signal was 
necessary (148); NKG2D and FcRIIIa (CD16) activating receptors provide the 
necessary secondary “kill” signal (149, 150). Further, NK cells can be “primed” by 
DCs to be more effective killers (151), and can also exhibit a form of 
immunological memory, similar to adaptive cells (152-154). Though able to 
provide immune defense by fast response and pathogen receptor recognition, 
NK cells have many functional features that make them an intermediate to the 
precisely targeted adaptive arm of the immune system. 
Innate responses are able to prevent infection from establishing and 
spreading by discriminating between foreign pathogens (PRRs) and self, but are 
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mostly non-specific. Most of these PAMP signaling pathways by PRRs overlap 
with sensing of tissue damage (DAMPs), including tumor-derived antigens (155). 
Thus, the innate immune system has a role in recognizing and responding to 
cancerous cells. Tumor neoantigens, RNA, and DNA can be sensed by TLRs, 
RIG-I (RLR), and STING, triggering the macrophage and DC production of 
cytokines, interferons, chemokines, and antigen presentation with T cell priming 
(156, 157).  The result is cancer cell death by eliciting apoptosis pathways, 
interferon signaling, or primed cytotoxic cells (158-160). Increased ligand 
expression provided by cellular stress or DNA damage of tumors cells help 
activate NK cells via their activating receptors (161) and cause direct tumor cell 
death by cytotoxic granules (perforin, granzymes), Fas-ligand or TRAIL, 
secreting IFN, and through antibody-dependent cellular cytotoxicity (162). 
Not only is the innate immune response of key importance in the initial 
stages of host defense, but it is also essential to the adaptive response, as the 
cells stimulated by microorganisms during infection, or tissue damage-associated 
tumor antigens, go on to activate antigen-specific defense directly and through 
cytokines and chemokine migration. PRR signaling that leads to macrophage 
and DC maturation, antigen presentation, and type I interferon production, in 
combination with NK cell pathogen recognition and activation, provide 
mechanisms of containment, whistle-blowing, and killing. These necessary first 
steps provide sufficient time for the induced T and B cell adaptive responses with 
high tumor cell specificity and cytotoxicity, explained further in the next section.  
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Adaptive response. As previously mentioned, the immune response consists of 
two arms: the innate component, an immediate though non-specific response 
consisting of myeloid cell pathogen sensing and cytokine and chemokine release 
for cellular recruitment and activation; and the adaptive component, a delayed 
but intricately more specific response largely reliant on the lymphocytic lineage of 
cells. Many of the responses of innate immunity are necessary for the adaptive 
immune system to get started. In brief, dendritic cells that are stimulated by PRR 
recognition increase their surface expression of MHC class II receptors and co-
stimulatory molecules which will allow them to activate naïve T cells once they 
migrate to peripheral lymphoid tissues and present antigen (163, 164). Once the 
lymphocytes are activated, the DCs die, and the T cells begin to proliferate and 
mature into cytotoxic CD8 effector T cells (165). The cytokines produced by the 
innate cells also encourage differentiation of naïve CD4 cells into Th1, Th2, 
Th17, TFH, or Treg effectors (166, 167), which then after DC activation, are able to 
‘help’ stimulate the antigen receptors of B cells to an effector state, or 
differentiate into plasma cells, and produce secreted antibodies against 
pathogens (168-170). Once activated, effector T cells reenter circulation and 
migrate back to the site of infection, following chemokine gradients and adhesion 
molecules (171). Serving as the cell-mediated responders of adaptive immunity, 
CD8 T cells can directly kill aberrant cells while CD4 T cells help to activate 
macrophages, neutrophils, and secrete protective and activating cytokines to aid 
in defense (172-174). Activated plasma B cells secrete antibodies specific to the 
foreign antigen to eliminate pathogens by humoral neutralization, opsonization, 
or complement activation (175). Thus, the adaptive response relies heavily on 
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innate immunity to be initiated and guided in order to achieve precise immune 
protection and disease resolution.  
 Originally, T and B lymphocytes develop from a common progenitor stem 
cell in the bone marrow (HSC), but T cell progenitors must migrate to the thymus 
for further stages of development into T cells. In the thymus, T cell progenitors 
acquire antigen-specific receptors, known as TCRs (T cell receptor), by random 
somatic rearrangement of DNA segments that specifically code for antigen 
binding regions of the receptor through a process called VDJ (variable-diversity-
joining) recombination. In total, VDJ recombination can produce up to 108 
different TCRs to match the wide variety of potential antigens (176), which are 
then further selected by their TCR reactivity to self-antigens (negative selection) 
and expression of CD4 or CD8 (positive selection based on class I (CD8) or 
class II (CD4) MHC molecules). Once T cells pass through selection and 
complete development, they home to secondary lymphoid organs such as the 
spleen or lymph nodes, and proceed to continuously circulate through these 
organs, lymph, and blood, awaiting the potential of antigen recognition and 
shedding their naïve status (177). Stimulated DCs, with antigen in tow, traffic 
from the origin of pathogen recognition to the inflamed or “reactive” lymph node 
and encounter scanning T cells, while concomitantly expressing CD80 and CD86 
co-stimulatory molecules (178-180). When an antigen-naïve T cell recognizes its 
cognate antigen presented on the MHC molecule of an APC, the T cell 
undergoes several changes: If the peptide is presented on an MHC class I 
molecule, which is broadly expressed on all cells, and activating cytokines such 
as IL-12 and IFN-I are present, naïve CD8 T cells will differentiate in to cytotoxic 
CD8 cells and undergo clonal expansion. If the antigen peptide is presented on 
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an MHC class II molecule, naïve CD4 T cells will differentiate into various CD4 
helper T cell subsets, dependent on the cytokines present in the environment, to 
be elaborated on in the next paragraph.  Additionally, T cell activation 
upregulates the expression of CD69 surface molecules to ensure the T cell stays 
in the supportive environment of the lymph node, with antigen, co-stimulation, 
and cytokines present, promoting proliferation of high (and moderate) antigen-
affinity T cells specific to that cognate antigen, called clonal expansion (181, 
182). During clonal expansion, the majority of expanded T cells down regulate 
CD62L and CCR7, allowing them to exit the lymph node and migrate to the sites 
of antigen source by way of chemokine gradients, integrins, and selectins, and 
perform their effector functions (183). For CD8 T cells, those effector functions 
include TNF and IFN cytokine production, and most especially, cytotoxic-
mediated cell death of the target cell recognized by its specific antigen 
peptide/MHC class I complex (184). This cytotoxic function is accomplished by 
cell-cell contact and delivery of perforin and granzyme toxic granules into the 
cytosol of the infected cell, lysing and killing the target cell (185, 186). 
 When DCs present antigen peptide on MHC class II receptors, naïve CD4 
T cells are activated to differentiate into multiple subtypes of effector and 
regulatory CD4 cells. After stimulation with antigen, CD4 cells begin to produce 
IL-2 to further promote their proliferation, and proceed towards differentiation into 
Th1, Th2, Th17, Treg, or TFH depending on the cytokines present at the activation 
site (187). IL-12 and IFN produced by macrophages and NK cells induces the 
differentiation of Th1 cells (188). Th1 cells are effector cells that support cell-
mediated immune response; they express transcription factor T-bet, and produce 
 34 
IL-2 and IFN to support macrophage and T cell proliferation and cytotoxicity 
(189), and protect the host from bacteria and viruses. IL-4 from basophils, mast 
cells, and eosinophils encourage differentiation into Th2 cells (190). Th2 cells are 
characterized by expression of transcription factor GATA3, are thought to support 
more humoral and allergic responses and defense against parasites, and 
produce suppressive cytokines IL-4, IL-5, and IL-13 (191). Th17 cells arise when 
IL-6 and TGF are present and are more pro-inflammatory cells, expressing the 
transcription factor RORT and producing IL-6 and IL-17 cytokines (192). They 
help to recruit neutrophils to the site of infection. TFH cells, or follicular helper 
cells, express the transcription factor Bcl6, and exist in the lymphoid follicles to 
help stimulate B cells to produce high-affinity antibodies (193). Unlike the other 
effector cells, cytokines involved in TFH differentiation are not completely known, 
but IL-6 is known to be important (194). TFH cells can produce cytokines that are 
similar to those of Th1 and Th2 cells, signaling to B cells which antibody isotype 
to secrete (195).  Effector CD4 cell responses act in defense by producing 
cytokines and chemokines that activate and recruit other immune cell subsets to 
their effector states. Because of this broad reaction, CD4 cells need to be more 
tightly regulated than the specific response of CD8 cells, and so only certain 
types of antigen presenting cells have MHC class II molecules. Treg, or regulatory 
T cells, also serve in this purpose. Treg cells suppress the immune response, and 
are key in preventing autoimmunity, by secreting IL-10 and TGF (196). There 
are two main groups of regulatory T cells: natural and inducible. Natural Tregs are 
committed to a regulatory fate while still in the thymus, and have high levels of 
surface CTLA-4 expression; inducible Tregs differentiate from naïve CD4 T cells in 
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the periphery under the influence of the environment (105). Induced Tregs arise 
when TGF alone is present in the lymph tissue, and like natural Tregs, induced 
Tregs express the FOXP3 transcription factor which prevents the transcription and 
production of IL-2 (197). CD4 and CD8 T cell differentiation are critical in host 
defense and entirely dependent on the type of cytokine signals produced from 
pathogen-activated innate cells, underlining the cohesiveness of the immune 
response. 
 As mentioned before, B lymphocytes differentiate from the same common 
progenitor as T lymphocytes, however B cells remain in the bone marrow. Like T 
cells, B cells also generate surface antigen-specific receptors, called B cell 
receptors (BCR), by way of somatic VDJ recombination (198). Unlike TCRs 
though, BCRs are expressed as an immunoglobulin molecule (Ig) with heavy and 
light chains that make up the antigen binding domain (199). The recognition of 
antigen by BCR not only can activate the naïve B cell directly, in conjunction with 
TLR stimulus (200), but it can also be internalized, processed, and presented 
back on MHC class II molecules for further antigen-specific CD4 T cell 
stimulation (201). The stimulated CD4 T cell then binds to the B cell by CD40 
ligand interaction, and produces activating cytokines for B cell proliferation and 
differentiation into antibody-producing plasma cells (202-204). IL-4, IL-5, TGF, 
or IFN are selectively secreted depending on the type of pathogen detected to 
induce specific antibody class production (205). Once secreted, antibodies 
function to kill the foreign pathogen by neutralization, opsonization, or 
complement activation (206). Neutralization involves antibody binding to bacterial 
toxins and viruses to prevent their interaction with normal host cells (207, 208). 
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Antibodies activate the complement immune response by binding the first 
complement proteins to the Fc region of the antibody, ultimately resulting in 
opsonization and phagocytosis, killing of the pathogen (209). The Fc region of 
antibodies can also activate other immune cells like NK cells to induce pathogen 
elimination (210, 211).  
  Cellular and molecular components of the innate and adaptive immune 
responses work together to resolve pathogen infections, tissue damage, and 
foreign bodies. For most acute diseases, once the danger is resolved, the 
inflammatory stimulus is removed and effector cells undergo apoptosis and 
phagocytosis. Some effector cells remain and differentiate into memory cells (B 
and T), who have the benefit of faster response times if the original pathogen or 
damage recurs (212, 213). Together, the immune response is the most powerful 
line of defense and management of infections, tumors, and disease. The inherent 
processes of both the innate and adaptive arms provide major targets for 
treatment strategies in effort to optimize the events that naturally occur. However, 
despite its effectiveness in protection and pathogen elimination, microorganisms 
and malignancies like cancer have developed ways to subvert the immune 
response, which will be addressed further in the following section. 
 
1.2.2: Mechanisms of Immunosuppression in Tumor Immunity 
 
As touched on previously, the genetic alterations and changes in cell 
regulatory processes in cancer cells often produce antigens from mutated genes, 
overexpressed genes, or cellular distress (DAMPs) (214, 215) that can be 
recognized by surveilling immune cells. These tumor antigens, either presented 
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on the cell’s MHC class I molecule or released from the cell in death, are sensed 
or picked up by APCs (macrophages and DCs) via TLRs, RLRs, or other 
sensors, triggering a pro-inflammatory response, and antigen processing and 
presentation (216). Once activated by these “danger” signals, APCs upregulate 
co-stimulatory ligands and traffic to proximal lymphoid tissue, such as the tumor 
draining lymph node, to prime the adaptive T cell and B cell response (217, 218). 
CD4 T helper 1 cells (Th1), CD4 T helper 17 (Th17) cells, CD8 T cells, and B 
cells in combination with NK cells and the other innate immune cells all play 
important roles in tumor inhibition by mechanisms similar to those for foreign 
pathogens (219, 220). Despite the host’s ability to stage an immune-mediated 
antitumor response however, incidences of tumor eradication, even with 
therapeutic assistance, are rare. In order to avoid elimination, tumors have 
developed strategies to evade immune detection, hinder immune activation, 
block tumor infiltration, and inhibit tumor-killing mechanisms. This section will 
provide an overview of the most common mechanisms of immune suppression 
co-opted by cancer cells to escape eradication, focusing on the immune cell 
types primarily affected. 
   
Loss of antigenicity and inhibition of sufficient immune activation by APCs. 
Tumors have developed a wide variety of ways to avoid detection by APCs as 
well as activated T cells. These evasive mechanisms result in decreased innate 
and adaptive cell activation and tumor-killing ability, leaving the tumor to continue 
thriving. Tumor cells have been shown to down regulate the expression of MHC 
class I molecules, evading detection by both DCs during initial surveillance, and 
antigen-specific T cells during the adaptive response (221, 222). Loss of MHC 
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class I molecule expression in tumors is associated with poor disease prognosis 
and clinical outcome (221). Tumor secreted factors such as VEGF (223), IL-6, 
and M-CSF (224) also cause defects in DC differentiation and maturation, 
resulting in less expression of MHC class II molecules and lack of expression of 
co-stimulatory molecules CD80 and CD86, making them unable to present 
antigen to T cells and activate the T cell response (225, 226). Lack of co-
stimulatory molecules can lead to T cell tolerance, anergy, and T cell death 
(227). In addition to the direct effects tumors have on DCs and T cells, tumors 
can acquire the ability to delete their own cells that express antigens T cells 
recognize, a process called “immune editing” (228). The loss of antigenic 
epitopes also occurs from many targeted cancer therapy treatments (229, 230). 
This loss of antigenicity can result in the evolution of tumor cell variants that are 
not recognizable to immune cells, leading to tumor progression (231, 232). The 
NKG2D activation receptor expressed on cytotoxic NK and T cells is a known 
responder to damage and stress-induced ligands in cancer. Tumor cells however 
can manipulate the expression of these ligands through post-transcriptional and 
post-translational regulation by misfolding, adenylating, splicing, or glycosylating 
the ligands in order to avoid immune recognition (233). Consequently, down 
regulation of antigens and inhibition of immune activation by loss of antigen 
presentation and co-stimulation represent two mechanisms utilized by tumors to 
evade the immune system. 
 
Immune exclusion. Despite the existence of cancer therapies that are tumor-
antigen specific, or involve blockade of tumor-suppressive chemical 
mechanisms, there remain many tumor types that exhibit little to no antitumor 
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response (234). This lack of response could be linked to physical obstacles 
prohibiting activated immune cells from infiltrating the tumors (235). The 
microenvironment of a tumor (TME) is characterized by not only by cancer cells 
and immune cells, but also blood vessels, fibroblastic cells, and extracellular 
matrix (ECM) (236). Studies have shown that stromal cells in the TME such as 
fibroblasts (cancer-associated fibroblast, CAFs), myeloid-derived suppressor 
cells (MDSCs), and tumor associated macrophages (TAMs) and the tumor 
vasculature all play a role in preventing immune infiltration. Reactive nitrogen 
species produced by MDSCs can trap T cells in the surrounding tumor stroma by 
nitration of chemokine CCL2 (237). CAFs can also trap T cells in the tumor 
periphery by secreting dense ECM proteins that inhibit T cell migration (238). 
High expression of Fas ligand (FasL) on endothelial cells in the tumor 
vasculature can induce CD8 cell apoptosis, preventing their infiltration, while 
simultaneously not excluding Treg cells because of their inherent high expression 
of apoptosis inhibitor c-FLIP (239). This mechanism is known as immune 
privilege. Immune cells can also be excluded from poorly vascularized and 
hypoxic tumors, caused by rapid tumor growth and expression of HIF-1 (240).  
Normalization of tumor vasculature by VEGF inhibition or deleting the signaling 
regulator Rgs5 can enhance T cell infiltration (241, 242). Until the problem of 
TME barriers can be overcome, the full benefit of immune cell therapies may not 
be realized. Thus, prevention of immune infiltration is a key mechanism exploited 
by tumors and their co-opted stromal cells in suppressing immune-mediated 
elimination. 
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Immunosuppressive ligands. T cell activation is a complex process not only 
involving antigen recognition, co-stimulation, proliferation and differentiation, but 
it also induces inhibitory pathways that can lead to eventual attenuation of T cell 
responses (243). In normal tissue homeostasis, negative-feedback responses 
called “immune checkpoints” are crucial to maintain self-tolerance and protect 
host tissue from potential damage induced during the immune response to 
infection (244). However, tumors and their microenvironment often have 
dysregulated expression of immunosuppressive receptors and ligands that 
regulate T cell effector functions, providing a mechanism of immune evasion. The 
high expression of antigens in cancer can also lead to the deterioration of T cell 
effector functions caused by continuous activation stimuli, a state termed 
“exhaustion” (245). Therefore, it makes sense that exhausted T cells are also 
characterized by expression of multiple inhibitory receptors. Immune inhibitory 
receptors such as PD-1, CTLA-4, TIM-3, LAG-3 and their ligands, among others, 
are expressed on tumor cells, T cells, and other immune cells in the TME 
including DCs, macrophages, fibroblasts, immature MDSCs, and Tregs (244), 
making the potential of receptor-ligand binding, and immune escape extremely 
likely. 
The most well studied immune checkpoints are CTLA-4 and the PD-1/PD-
L1 pathways. Programmed cell death (PD-1) receptor is induced upon T cell 
activation and is intended to limit T cell effector functions by decreasing their 
production of inflammatory cytokines and cell survival proteins (246, 247). It’s 
ligands, PD-L1 and PD-L2, are most often expressed in peripheral tissues by 
tumor cells and myeloid-derived cells in the tumor microenvironment (248). The 
PD-1/PD-1/PD-L2 pathway gene expression can be upregulated on tumor cells 
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and cells in the TME as a consequence of constitutive oncogenic pathway 
signaling (249), and in response to therapy, HIF-1 expression and hypoxia 
(250), immune-associated cytokines such as IL-10, TGF and IFN (251, 252), 
and tumor-secreted factors such as VEGF and PGE2 (253). PD-1 can also be 
induced on NK cells and B cells as well as Tregs, limiting their lytic and effector 
activities (254, 255) or promoting their proliferation and immune suppressive 
function (256), respectively, exhibiting another mechanism of immune resistance. 
Unlike PD-1, cytotoxic T lymphocyte associated protein-4, or CTLA-4, 
predominantly regulates T cell activation, but is also important in maintaining 
immune tolerance and avoiding autoimmunity, and thus can be found more 
broadly in host tissues and secondary lymphoid organs, as well as the tumor 
microenvironment (244). CTLA-4, which is expressed upon T cell activation, has 
very high homology to CD28 co-stimulatory receptor, but binds to B7 (CD80/86) 
receptors on APCs with much higher affinity than CD28; thus, it is believed to 
outcompete CD28 for receptor binding, resulting in lack of T cell activation (257, 
258). To produce its inhibitory effects, CTLA-4 interferes with the TCR signaling 
chain, and by removing the active pool of CD80/CD86 from APC surfaces (247, 
259). Despite inhibiting CD8 effector T cells, the major effects of CTLA-4 
signaling come from down-modulation of CD4 helper T cell activity (Th2) and 
increasing Treg immunosuppressive functions (260, 261).  
 Other checkpoint receptors have been more recently discovered and 
investigated, including TIM-3, LAG-3, BTLA, A2aR, KIRs and others. These 
molecules are expressed on T cells, NK cells, and TME-associated endothelial 
cells, macrophages, APCs, and Tregs, induced from inflammatory signals and T 
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cell activation (244, 262, 263). They have been shown to inhibit NK, CD8, and 
CD4 helper T cell activity, cytotoxicity, and promote anergy and Treg proliferation 
and function (264-266).  
Therefore, immunosuppressive receptors and ligands represent one more 
mechanism co-opted by cancer cells to combat the immune response. 
 
Immunosuppressive cells. In addition to the loss of antigenicity and ability to be 
recognized, creation of barriers to prevent immune infiltration, and induction of 
inhibitory receptors, tumors can co-opt stromal and immune cells in the TME to 
aid in suppressing effector cell functions and evade extinction. Often 
encompassed in the total tumor infiltrating lymphocytes, Tregs play an important 
role in immunosuppression by secreting anti-inflammatory cytokines such as IL-
10, IL-35, and TGF, competing for activating cytokines like IL-2 with effector 
cells (267), and by direct contact with CTLA-4 (268), adenosine (269), and 
cytotoxic cytokines to inhibit DCs and effector T cell function (270, 271). Treg 
differentiation is induced by antigenic stimulation in the presence of TGF (272), 
and naturally formed Tregs can traffic to the tumor site via tumor and macrophage 
secreted CCL22 (273). TGF itself can disrupt T cell activation directly as well as 
by limiting the mobility and survival of DCs (274), and by promoting polarization 
of tumor associated macrophages that sequester tumor antigen (275), 
contributing to inhibition of T cell priming. Macrophages and undifferentiated 
monocytes in the TME can be influenced by environmental cues to preferentially 
differentiate into M2 macrophages (276). M2 macrophages are induced by IL-4 
and IL-13, typically produced by Th2 helper cells, and are deemed 
 43 
immunosuppressive because they contribute to the production of IL-10 and 
arginase, inhibitors of T cell activation (277). Immature myeloid cells known as 
MDSCs are recruited to the TME by GM-CSF, IL-6, and CCL2, often produced 
from tumor cells (278). Major MDSC-mediated mechanisms of immune 
suppression are promoted by TGF- (279) and include nitrosylation of the TCR 
and T cell surface proteins to inhibit T cell effector function (280), and expression 
of arginase to deplete arginine nutrients from the TME (281). Suppressive 
subsets from the myeloid lineage have overlapping abilities to express 
immunoregulatory molecules such as arginase, iNOS, and indoleamine 2,3-
dioxygenase (IDO) to inhibit CD8 cell proliferation or induce apoptosis (282). IDO 
and arginase are metabolic enzymes that can catabolize essential amino acids, 
tryptophan and arginine, used by T cells for inducing proliferation, cell cycle 
growth, and effector functions (283-285). iNOS also catabolizes arginine to form 
nitric oxide (NO), a reactive nitrogen species used by MDSCs, utilized for 
nitrosylation of the TCR to interfere with TCR binding peptide-MHC complexes 
and promote hyposensitivity and tolerance (286), and nitration of chemokines 
used in T cell recruitment (237).  
Many of the cellular interactions in the TME are complex, showing 
redundancy in suppressive action, or cytokine profiles having positive feed-back 
loops supporting the differentiation and function of immunosuppressive cells. In 
addition to the few mechanisms described here, tumors have many other 
immune resistance mechanisms, a product of their constant need for evolution to 
maintain survival. It has been shown that tumors can become resistant to 
cytotoxic cytokines, shown by the development of tumor-IFN insensitivity from 
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the absence or dysfunction of IFN receptor signaling pathway (287). Tumor cells 
can also lose the expression of genes necessary for cytotoxic signaling such as 
JAK family members and genes of the IFN pathway, promoting resistance to 
immune-mediated killing (288, 289).  
 
1.2.3: Summary 
The innate and adaptive immune system are evolutionarily advanced in their 
ability to cooperate to resolve danger within their host. Humans have developed 
intricate pathways to detect foreign pathogens and cancer, following up sensing 
with action, by activating the effector cells and molecules of immune protection. 
However, tumors have developed ways to counteract and suppress the 
defensive activity of our immune system at most turns. The most interesting 
aspect of tumor-immune suppression is that most of the cells and molecules 
utilized by tumors to promote their own survival are inherently purposed for self-
tolerance to prevent autoimmunity. Despite this fact, many of the suppressive 
mechanisms tumors have acquired such as checkpoint inhibitors and 
immunosuppressive cells can be therapeutically targeted to repolarize the TME 
into an antitumor phenotype, which will be reviewed in the following section. 
 
1.3: Immune Therapy: Overcoming Tumor-Immunosuppression 
 
As reviewed above, humans are equipped with extensive protective 
mechanisms that enable the detection and recognition of foreign pathogens and 
damage, or cancer associated markers. This identification process initiates a 
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cascade of signaling, recruiting an immediate cellular and chemical response to 
instigate inflammation at the source of trouble, killing microorganisms and cells in 
a non-specific but timely matter; while behind the curtain, an intricately more 
specific immune response ramps up to deliver a precise second wave attack. 
Despite the involved, sophisticated, and specific process that is the immune 
response, pathogens and cancer in particular have simultaneously evolved ways 
to suppress and evade it in order to continue surviving. These include tumor-
induced impairment of antigen presentation and negative regulation of APC 
function and development; creation of a physical barrier to infiltration T cells by 
utilization of fibroblasts and stromal cells in the tumor microenvironment; 
promoting upregulation of pro-apoptotic and immunosuppressive cytokines, 
ligands, and receptors to inhibit cellular mediators of cytotoxic response; and 
drafting and recruiting of immunosuppressive cells from the microenvironment 
and circulation to further inhibit effector cells of the immune system (234, 290). 
The vast mutational landscape and heterogeneity of tumors between 
patients, and even between different areas of the same tumor, make 
personalized medicine targeting specific gene mutations challenging. Given the 
potent immunosuppressive capacity of tumor cells, infiltrated suppressive 
immune cells, the surrounding tumor stroma, and the propensity of immune cells 
to respond to cancer antigens in similar ways across patients, targeting the 
suppressive pathways tumors co-opt for self-promotion presents an attractive 
intervention for cancer treatment. Many investigators have pointed their 
therapeutic inquiries towards T cells as the major effector cells of the tumor 
response, developing antibodies that can antagonize suppressive molecules and 
cells, cytokines and molecules to agonize T cell effector functions and reverse 
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tolerance and anergy, or adoptively transferring activated cells into the tumor 
environment itself (291).  Others have taken on a more holistic approach in 
targeting cells or pathways of the innate immune response that enable the 
efficacy of the adaptive response (292).  
This section aims to provide current knowledge on immune therapies 
utilized in the treatment of cancer, including immune checkpoint blockade, 
stimulators of the innate immune response, and efforts to combine therapies 
directed at components of the innate and adaptive immune arms. Studies 
discussed will be broadly in multiple tumor models, but with special attention to 
those currently used for bladder cancer.  
 
1.3.1: Therapeutic Targeting of Immune Checkpoints 
 
Inhibitory checkpoints. Immune checkpoints are biologically important for 
maintaining self-tolerance and limiting bystander tissue damage during the non-
specific innate immune response and hyper-activated adaptive immune response 
(293). However, these anti-inflammatory processes can be commandeered by 
tumors to evade immune-mediated destruction. In the treatment of cancer, 
immune checkpoint blockade removes these inhibitor signals to NK, 
macrophage, and T cell (effector cell) activation and function, enabling antitumor 
immune cells to overcome regulatory mechanisms established by tumors, and 
eliminate them (294). Inhibitory checkpoints like CTLA-4, the PD-1/PD-L1 axis, 
TIM-3, and LAG-3 all have different mechanisms to make immune cells, 
particularly T cells, quiescent, and therefore different therapies have been 
developed to address them. 
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 CTLA-4, as discussed previously, has very similar homology to CD28, and 
therefore shares the same ligands CD80 (B7.1) and CD86 (B7.2), necessary for 
APC-mediated co-stimulation and activation amplification of T cells (295).  
However, CTLA-4 has over 100x more affinity for both CD80 and CD86, and its 
engagement with either ligand down-modulates the amplitude of T cell 
responses, typically at the site of T cell priming in secondary lymphoid organs 
(261, 296, 297). Expression of CTLA-4 is upregulated upon T cell activation on 
the cell surface and at the immunological synapse (298), and is thought to be 
more predominantly expressed on CD4 T helper cells, insinuating that 
heightened T cell responses seen with CTLA-4 inhibition are due to promoted 
activity of CD4 T cells on other immune subsets (CD8 T cells) (299). CTLA-4 
expressed on Tregs also has a role in attenuating the effector T cell response 
(300). Therefore, blockade of CTLA-4 with inhibitory antibodies has been shown 
to enhance tumor rejection by inhibiting Treg function and Treg killing (301, 302), 
enhance CD28 co-stimulation and T cell activation, and thus expansion of tumor 
antigen-specific CD8 T cells (303). It does this by blocking CTLA-4 competition 
for costimulatory ligands by antagonistic antibody binding to the interaction 
domain on B7 (304). Anti-CTLA4 therapy also leads to the expansion of effector 
CD4 populations (305), as well as exhausted CD8 populations (306).  In humans, 
anti-CTLA-4 therapy with ipilimumab (307) antibody produced a 3-year survival 
rate of 21% in metastatic melanoma patients (308), and similarly a 5-year 
survival rate of 20% was observed patients treated with tremelimumab (anti-
CTLA-4 mAb) (309). Unfortunately, as anti-CLTA-4 therapy is effectively lowering 
the activation threshold and taking the brakes off of effector T cells, many 
patients experience immune-related adverse events while on therapy (310). This 
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is also potentially due to CTLA4 blockade-associated TCR repertoire broadening 
which increases T cell functional reactivity (311). 
 The PD-1/PD-L1/PD-L2 axis serves primarily to maintain tolerance and 
dampen T cell responses in the periphery (312), and similar to CTLA-4, its 
expression as both receptor and ligands is induced upon B and T cell activation, 
and as a byproduct of the immune response on many cell types in the TME 
(313). PD-L1 and PD-L2 are widely expressed on non-lymphoid tissues and 
actively upregulated in response to inflammatory cytokines like IFNs (314). 
Unlike CTLA-4, PD-1 signaling directly interferes with the TCR signaling cascade 
to regulate T cell activation (315). Persistent PD-1 signaling also induces 
metabolic restriction, inhibiting glycolysis while simultaneously promoting fatty-
acid oxidation (FAO) and lipid catabolism, perpetrating T cell exhaustion (316, 
317). Blockade of PD-1 signaling can reinvigorate effector cells and antigen-
specific T cells by preventing the attenuation of TCR signaling, effectively jump-
starting exhausted T cells to proliferate (318). It has also recently been shown to 
reverse negative metabolic reprogramming induced by PD-1 signaling (319).  
Because of the propensity of PD-1 ligands expressed in tumor tissue and by 
immune cells of the tumor stroma, it has been suggested that the effectiveness of 
PD-1 therapy is reliant on the bulk of effector cells to be already present in the 
TME (320). Early large scale clinical trials with anti-PD-1 antibody Nivolumab 
have shown successful antitumor responses in patients, with objective response 
rates of 17%, 27%, and 31% in NSCLC, RCC, and melanoma, respectively. 
However, exhausted T cells have a distinct epigenetic profile that can limit T cell 
reinvigoration, and thus PD-1 blockade may not be sufficient to functionally 
restore T cells once they meet a certain exhaustion threshold (321, 322). 
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 Other inhibitory checkpoints are currently being explored preclinically and 
in clinical trials as the “next generation” of checkpoint blockade therapy. 
Lymphocyte activation gene 3 (LAG-3) is highly homologous to the CD4 T cell 
co-receptor, and as such its ligand is the MHC class II molecule (323); however 
new work has found a potential additional ligand as LSECtin (324). As previously 
mentioned, LAG-3 is expressed on T cells, B cells, NK cells, and DCs in 
response to activation, and serves as a negative regulator of T cell expansion 
and DC activation as it competitively binds with MHC II (325, 326). T cell 
immunoglobulin and mucin-3 (TIM-3) is marker for exhaustion in combination 
with other checkpoints, expressed on activated T cells, NK cells, Tregs, DCs, and 
monocytes, and negatively regulates Th1 type immunity. TIM-3 functionally binds 
to galectin-9 (265), PtdSer (327), HMGB1 (328), and CEACAM-1 (329) to 
promote immune cell dysfunction and apoptosis by negatively regulating TCR 
signaling, and other mechanisms not fully clarified (330, 331). VISTA, B7-H3, and 
TIGIT all represent other recently identified immune inhibitory receptors that 
negatively regulate T cell activity, and are currently being investigated further to 
understand their mechanisms of action (299). 
 
Co-stimulatory checkpoints. Immune activation is mostly regulated by two 
major receptor families: the immunoglobulin-like (Ig) superfamily, consisting of 
co-stimulatory receptors CD28 and inducible T cell co-stimulator (ICOS), and the 
TNFR superfamily, consisting of co-stimulatory receptors OX40, CD27, 4-1BB, 
CD40, and GITR (332, 333). A general theme in the function of these stimulatory 
receptors, and potential antibodies that may be used to agonize them 
therapeutically, is that the resulting effects will be 1) activation of APCs, 2) 
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reduction in Treg suppressive activity and 3) co-stimulation of CD4 and CD8 T 
cells and NK cells, based on the cells that express the receptor (334).  
The Ig superfamily comprises receptors that express a variable 
immunoglobulin-like domain that binds to cognate ligands expressed on APCs; 
for ICOS, the ligand is B7H (335). ICOS is upregulated on activated T cells, B 
cells, and ILC2 cells and serves to enhance type I and II immune responses, Treg 
maintenance, TFH differentiation (294). It regulates the production of IL-4 (336), 
antibody isotype switching (337). ICOS signals though PI3K/AKT signaling and 
also enhances calcium signaling (PLC) (338), suggesting it has a role in cellular 
metabolism, protein translation, and apoptosis (339). In preclinical studies, 
agonist antibodies to ICOS have shown antitumor potency and activation of 
effector immune responses similar to antagonistic blockade of its other Ig 
superfamily inhibitory members (340). However, antagonist antibodies to ICOS 
also show positive effects in dampening Treg functions (340). Studies are 
ongoing, but much more needs to be learned about the dual effects of ICOS and 
its ligand to better understand its therapeutic use in patients. 
The TNFR family members are appealing candidates for targeted 
therapies, with the greatest attention being laid on OX40 and 4-1BB. 4-1BB 
(CD137) is an enhancer of T cell co-stimulation, through signaling of TRAF1 and 
TRAF2 (341). 4-1BB or its ligand 4-1BBL are expressed on activated T cells, NK 
cells, monocytes, DCs, and B cells. Ligation on T cells results in upregulation of 
anti-apoptotic genes and protection from activation induced death, promoting the 
differentiation of memory T cells (342). In preclinical trials, agonistic 4-1BB 
antibody enhances antitumor T cell responses and enables tumor rejection (343), 
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however in clinical studies in patients, there is evidence of serious immune 
related adverse events, and so dosing, timing schedules, and combination 
approaches are still under investigation (344). OX40 is present on activated T 
cells, Tregs, NK cells, NKT cells, and neutrophils, and its ligand is expressed on 
APCs and T cells as well. Its ligation has been shown to inhibit Treg suppression, 
and sustain and enhance CD4 T cell responses, as well as CD4 and CD8 T cell 
survival and memory generation (345, 346). It regulates survival signaling though 
Bcl-2/Bcl-xL and also enhances PI3K/AKT signaling (347). Similar to 4-1BB, 
preclinically OX40 agonist antibodies increase anti-tumor activity (348), and DCs 
with enhanced OX40 expression can enhance tumor rejection in a CD8, CD4, 
and NK T cell dependent manner (349). Therapeutic agonism of OX40 in patients 
has not been completed on a large scale, but it has been shown to induce 
proliferation of effector T cells and augment tumor-immune responses (350). 
GITR, CD27, and CD40 and their ligands are expressed on T cells, B cells, NK 
cells, APCs upon activation, and through their own signaling schemes likewise 
are important for promoting T cell and NK cell activation and proliferation, 
humoral immune response (CD40), APC maturation, inhibiting Treg function 
(GITR), and generating T cell memory (CD27) (351-354). While proving to be 
exciting new targets in the field of cancer therapy, the fundamental biology of 
these molecules remains underdeveloped, and is being outpaced by clinical 
investigations, so there is much still to be learned regarding their function and 
signaling paths. 
 
1.3.2: Innate Immune Stimulation 
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Toll-Like Receptor Agonists. Immune checkpoint blockade and adoptive cell 
transfer of antigen-specific T cells have owed their therapeutic success to the 
improved function, recruitment, and activation of T cells, or more broadly, the 
adaptive immune response. Historically, the best responders to these therapies 
are patients with tumor subtypes that are highly CD8 T cell infiltrated, have 
chemokine signatures and other indicators of chronic inflammation, have high 
mutational burdens, and typically include high expression of immune inhibitory 
factors such as PD-L1, IDO, or Tregs, among others. However, macrophages, 
DCs, NK cells, and other cells of the innate immune system, via their roles in 
antigen recognition, presentation, T cell co-stimulation and direct tumor cell 
killing, are essential for the initiation, maintenance and programming of antitumor 
immune reactions, making them attractive targets for therapeutic exploitation. 
Toll-like receptor stimulation, as one of the best defined PRR pathways, can 
serve as a key activator of an antitumor response, aimed at waking up the host 
immune response when spontaneous T cell priming has not occurred (292).  
Down regulation of antigen expression and suppression of APC 
maturation and priming are some strategies that tumors have cultivated in order 
to evade innate immune recognition. As previously discussed under the innate 
immune response, TLRs expressed on immune cells are type I transmembrane 
proteins that have fundamental roles in the detection of diverse microbial 
signatures. TLRs 2, 4, 5, 6 detect proteins, peptidoglycans, lipids (LPS), and 
bacterial flagellin extracellularly, while TLRs 3, 7, 8, 9 detect single-stranded or 
double-stranded RNA, and CpG modification of DNA residues (CpG-ODN) 
intracellularly (Table 1). Several ligands agonizing theses TLRs have already 
been approved, and used in cancer therapy: TLR2/4 agonist BCG, TLR4 agonist 
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monophosphoryl lipid A (MPL), and TLR7 agonist imiquimod (355-357).  Others 
such as TLR5 agonist Entolimod, and TLR7 agonist 852A are still being 
investigated in preclinical and clinical trials (358, 359). 
Focusing more on the Th1 immunity-inducing TLRs, nucleic acid sensing 
TLRs (3,7,8,9) are relevant to cancer detection as they can recognize DAMPs 
from cellular debris of necrotic or dying tumor cells (360). Upon ligand binding, 
these TLRs induce signaling cascades through NF-kB and interferon regulatory 
factors (IRFs) to promote the transcription of inflammatory cytokines and IFNs-I 
(361). TLR7 agonist imiquimod has shown antitumor effects in basal cell 
carcinoma, with more limited activity in melanoma and breast tumors (356, 362). 
It is believed to aid in recruitment of tumor-infiltrating plasmacytoid DCs (pDCs) 
and macrophages by cytokines TNF, IL-12, and IFN, leading to further 
infiltration of helper T cells (363). Imiquimod is being further tested for use in 
noninvasive bladder cancer (364) and as an adjuvant to cancer vaccines in 
several solid tumors (365). Resiquimod, a dual TLR7/8 agonist, has been shown 
to more potently induce cytokine expression than TLR7 therapy alone (366). 
Clinical studies in skin tumors have shown improved recruitment of effector T 
cells, antigen-specific CD4 T cell responses, and tumor cell elimination (367, 
368). TLR9 ligation by unmethylated cytosine-guanosine (CpG) DNA induces 
type I IFN production, activating DCs, NK cells, and tumor-specific CD8 T cells 
and generating tumor regression (369). CpG ODNs (oligonucleotides) are 
synthetic agonists of TLR9 which are most actively being explored in solid and 
hematologic cancers as both monotherapies and adjuvants (370). CpG ODN and 
TLR9 agonist SD-101 has demonstrated the ability to overcome tumor resistance 
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to checkpoint blockade therapy and increase effector T cell infiltration in 
preclinical studies (371); clinical trials in humans are ongoing. TLR3 stimulation 
by recognition of double-stranded RNA dsRNA induces the secretion of type I 
IFNs, similar to TLR9, but also can lead to direct activation of apoptosis of tumor 
cells (372). In addition to stimulating TLR3, is activates RLR sensing, instigating 
a two-pathway production of IFN-I (373).  Poly(I:C) is a synthetic dsRNA that is 
being explored preclinically and clinically in the treatment of many solid cancers, 
including bladder cancer (373, 374). Poly(I:C), and derivatives of it have been 
shown to inhibit tumor growth and promote tumor infiltration of activated immune 
cells (375-377), however most of its uses and successes in patients are as an 
adjuvant therapy (378). 
 Though not a TLR, STING PRR agonists are also being exploited in 
cancer therapy. To review, like TLR9, cytosolic enzyme cyclic GMP-AMP 
synthase (cGAS) senses foreign DNA within the cell cytosol and synthesizes 
dinucleotide cyclic GMP-AMP (cGAMP) (379). cGAMP is then able to bind and 
activate STING, initiating pro-inflammatory signaling that induces IFN-I 
transcription and NF-kB mediated production of IL-6, IL-15, TNF, and IL-1 (380-
382). STING signaling is important for the generation of tumor-specific CD8 T cell 
responses and tumor regression (383). STING agonistic cyclic dinucleotides 
such as cyclic di-GMP and 2’3’-cGAMP are utilized in therapeutic investigation 
because of their affinity, stability, and specificity for STING (384). Preclinical 
studies have found that STING agonists can suppress cancer metastasis, 
increase CD4 and CD8 T cell recruitment, and stimulate IL-12 production by 
MDSCs, furthering the activation of inflammatory cells (385, 386). Initial clinical 
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studies of STING agonist (DMXAA) in humans proved unsuccessful due to poor 
CDN binding to STING (387), but new agonist structures are currently being 
investigated in clinical trials alone and in combination with another 
immunotherapy. 
Recent studies have identified TLR expression on cancer cells 
themselves, linking their expression with diseases progression, metastasis, and 
shortened survival (388, 389). The potential dual agonistic and antagonistic role 
in cancer inhibition or progression, as well as their potential serious adverse 
effects, including cytokine storm, have drawn caution to the use of TLR 
stimulants in immunotherapy (390). Despite some hesitancy, the use of TLR 
agonists has shown definitive antitumor benefits by activating immune cells in the 
TME, and inducing the expression of pro-inflammatory cytokines that facilitate 
immune infiltration and inhibit oncogenic signaling in the tumor. In many cancers, 
though TLR agonists show efficacy, more work needs to be performed to better 
define their mechanisms of action to ensure confidence for their use in humans. 
 
Cytokine therapy: Interferon-alpha. Interferons have a pleiotropic role in the 
stimulation of antitumor immunity. As previously mentioned, almost all cells are 
capable of producing and responding to IFN-I, however pDCs are able to secrete 
higher levels of type I IFN than any other cell type. Often, type I IFN induction is 
the product of stimulation of TLR, RLR, or STING signaling pathways. Activation 
of IFN receptors leads to a multifaceted response including but not limited to: 
promotion of NK cell function (391), support for DC maturation, migration, and 
antigen presentation/priming to activate T cells (392), stimulating chemokine 
production for immune recruitment (118-120), and direct cell killing through 
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TRAIL-mediated apoptosis (393); but counter-productively, it can induce immune 
suppressive enzymes such as IDO (394), and increase expression of PD-L1 on 
stromal and cancer cells (395), contributing to tumor-immune evasion. 
Preclinically, IFN-I production has been shown to be critical for CD8+ DC cross-
presentation to CD8 T cells, generating antigen-specific immunity and tumor 
rejection (396, 397). Exogenous IFN and IFN delivery to tumors by either 
association with transferred monocytes or conjugation to antibodies resulted in 
impeded growth and metastasis (398, 399). There is also evidence that the 
production or delivery of IFN-I can help mitigate tumor-induced suppressive 
immune cells (400), thereby overcoming some mechanisms of immune 
avoidance. Although the process of immunoediting, in which tumors cycle 
through elimination, equilibrium, and evasion with the immune response, can 
produce mechanisms of resistance to immune-mediated tumor eradication, type I 
IFNs intervene in all of these phases (401, 402). 
 In bladder cancer specifically, IFN has been investigated as a salvage 
therapy in NMIBC after BCG failure due to its anti-proliferative activity on tumor 
cells. Both IFN and IFN have also shown to inhibit tumor growth by inhibiting 
angiogenesis and expression of VEGF and basic fibroblast growth factor (FGF) 
in human xenograft orthotopic mouse models of bladder cancer (403-405).  
However, when using recombinant IFN protein in experimental strategies, 
antitumor-related results were not durable due to unsustainable IFN levels 
(406). To overcome these limitations, intravesical gene delivery of IFNα through 
the use of adenoviral encoding IFNα (Ad-IFNα/Syn3, i.e. Instiladrin) was 
developed (407), and early clinical trials have shown its safety and efficacy in 
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treating BCG Unresponsive NMIBC (66, 67, 408). Clinical studies evaluating the 
use of intravesical Ad-IFNα/Syn3 in the bladder are ongoing. IFNs-I direct and 
indirect effects on tumor cells, the TME, and the immune system have been 
described broadly in multiple cancer models. Because IFN’s mechanisms are 
diverse, its precise role in the immune response to cancer has only begun to be 
understood in bladder cancer, and they could be distinct between tumor types. 
Elucidating IFN’s immune-mediated antitumor mechanism in bladder cancer is 
therefore critical for interpreting patient response, identifying effective 
combination therapies, and improving the treatment of bladder cancer. 
 
1.3.3: Current Status of the Therapeutic Utility of Single and Combination 
Immune Therapy 
 
Immune checkpoints. Remarkable advances in immunotherapy treatment for 
cancer have occurred in recent years. Approaches aimed at co-activating 
different tumor inhibitory pathways with immunotherapy, radiotherapy, targeted 
molecular therapy, and chemotherapy are widely used. Most immune 
checkpoints are non-redundant, leaving the possibility of combination checkpoint 
blockade, or antagonist/agonist approaches open. Based on understanding of 
how CTLA-4 and PD-1 act to attenuate T cell activity (activation and effector 
function, respectively), it is believed that anti-CTLA-4 and anti-PD-1 therapies 
can act at different stages of the cancer-immune response (87). Single agent 
checkpoint inhibitors have seen successful activity in advanced and metastatic 
malignancies, as discussed previously, with roughly 20% survival rates (anti-
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CTLA-4) and 30% response rates (anti-PD-1) in patients with melanoma, non-
small cell lung cancer, and renal carcinoma (308, 409-412). However, treatment 
of patients with combination checkpoint inhibitors produced longer median 
progression-free survival (PFR) rates than either therapy alone (413, 414). Other 
inhibitors and stimulators of checkpoints, notably TIM-3, LAG-3, ICOS, 4-1BB, 
and OX40 among others, are currently being investigated as single agents, and 
in combination with anti-PD-1/PD-L1/CTLA-4 therapies (415). Progress that has 
been achieved through monotherapies is notable, however certain aspects of the 
TME may limit tumor responses, for example by upregulation of additional 
checkpoint molecules to limit single agent treatment efficacy (294). Targeting 
immune checkpoints improves patient median survival and also can provide long-
term durable responses, and combinatory immunotherapies may lead the pack in 
increasing the number of patients who continue to see clinical benefit over time.  
 
Innate immune stimulators. For poorly immune-infiltrated tumors, providing 
inflammatory signals to facilitate recruitment of activated effector cells is 
beneficial in fighting tumor progression. This can be seen with single agent 
recombinant viral vector therapy, exogenous cytokines, and TLR agonists, used 
to incite chemokine production and an inflammatory response (416). However, 
therapeutic potential of PRR agonists have focused on their adjuvant use in 
activating an immune response, and most successes in cancer have come in 
combination therapy with checkpoint inhibition, adoptive cell transfer, or cancer 
vaccines, rather than as a single agent. Treatment with exogenous cytokines can 
promote cytotoxic activity of effector CD8 T cells and NK cells, and differentiation 
of CD4 T cells into T helpers; however, some cytokines can expand Treg 
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populations and promote nonspecific activation of immune cells with associated 
toxicities (417). To limit these adverse effects, current clinical trials are 
investigating modified inflammatory cytokines like IFN-I, IL-15, and IL-2 in 
combination with checkpoint inhibitors, utilizing more targeted delivery tactics 
rather than systemic approaches. Immunotherapeutic strategies that 
simultaneously target the innate and adaptive immune response are suggested 
to reduce immune tolerance, and are effective in eliminating large tumors (418, 
419). The combination of TLR agonists and checkpoint blockade is thought to 
augment T cell activation and to potentially overcome resistance to checkpoint 
blockade by priming APCs to enhance the adaptive immune component (361). 
Indeed, combination of TLR9 agonist CMP-001 with anti-PD-1 Ab 
pembrolizumab was reported to reverse PD-1 inhibition resistance with no 
maximum tolerated dose (420). Clinical studies of the combination of TLR 
agonists with checkpoint inhibitors have also shown increased levels of APCs in 
the TME and suppression of head and neck cancers (421). Many trials are 
ongoing with the combined use of TLR3, 4, 7, 8, 9 and STING agonists with anti-
PD-1 antibody, anti-CTLA4 antibody, or a combination of all three (361, 377). To 
move forward in improving patient responses, care providers need to have an 
arsenal of weapons to meet cancer at every turn. Mechanistically speaking, the 
ability to use an innate stimulator to jump start a lagging immune response but 
coincidentally may increase tumor evasion mechanisms, followed by an adaptive 
targeted therapy like checkpoint inhibition to combat the Stimulator’s induced 
evasion is akin to cutting off cancer’s support legs. 
 
1.3.4: Summary 
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Humans are equipped with the exquisite defensive tools of the immune system to 
fight off pathogens, cellular dysregulations, and cancer. Despite our intrinsic 
innate and adaptive mechanisms, malignancies like cancer have evolved 
strategies to avoid our immune system and continue surviving. Therapeutic 
intervention with drugs designed to reverse immune-suppressive mechanisms 
has proved to be a successful venture in tumor inhibition. Many therapies 
antagonizing immune inhibitory checkpoints, or agonizing intrinsic innate immune 
activation or stimulatory checkpoints are either approved or being investigated for 
use in patients today. It’s important to keep in mind, as these therapies are 
designed to increase effector cell responsiveness and inhibit suppressive 
mechanisms that adverse reactions and tissue damage due to highly stimulated 
cytotoxic cells will occur. Ultimately, the balance of harm versus benefit must be 
constantly monitored to ensure patient safety, treatment efficacy, and clinical 
ethics. 
 For bladder cancer, BCG therapy in NMIBC already capitalizes on TLR 
stimulation to produce antitumor efficacy, though there is room for improvement 
for patients who exhibit disease progression, recurrence or no response to BCG. 
For more aggressive tumors, the approved use of checkpoint inhibitors in bladder 
cancer has demonstrated improved overall response rates for locally advanced 
and metastatic disease, and is continually being studied in combination settings 
(422-424). The use of Ad-IFNα therapy for BCG Unresponsive patients may be 
able to fill the need of an alternative immune stimulatory treatment, inducing TLR 
recognition and endogenous IFN-I production, to control and treat NMIBC. 
However, one of the qualms of BCG is the incomplete understanding of its 
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mechanism of action; as IFN is a pleotropic cytokine, elucidating its specific 
immune-mediated antitumor mechanism is therefore critical for interpreting 
patient response, identifying effective combination therapies, and improving the 
treatment of bladder cancer.  
I hypothesized that IFN specifically induced recruitment and activation of 
immune cells into NMIBC tumors, leading to more robust antitumor responses 
alone and in combination with checkpoint blockade therapy. First looking at 
patients to determine the validity of these questions, I found that treatment with 
Ad-IFNα therapy induced expression of T cell markers and checkpoint markers 
within NMIBC tumors, and a plethora of inflammatory cytokines compared to 
before treatment. This finding encouraged further investigation into the MB49 and 
BBN murine bladder cancer models to determine which immune cells were most 
crucial in the IFN-mediated antitumor response, and if and how they were 
recruited to the tumor. The patient data also encouraged finding the utility of 
combination immunotherapy with IFN and checkpoint blockade (anti-PD-1) 
treatment on mouse bladder cancer tumors, to see if there were synergistic 
effects on tumor inhibition and survival. The results are detailed in the next 
chapters. 
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Chapter 2: Effects of Ad-IFN Therapy in Patients with NMIBC 
 
This work is based upon “Inhibition of urothelial carcinoma through targeted type 
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M, 
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D, 
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission from 
Oncoimmunology. 
 
2.1: Introduction 
 
Non–muscle-invasive bladder cancer (NMIBC) comprises ~70% of 
diagnosed urothelial carcinomas (UC) (9). Although not immediately life-
threatening, they have a propensity to recur and progress. Intravesical therapy, 
mainly in the form of Bacillus Calmette-Guerin (BCG), is administered to prevent 
recurrence, delay progression, and provide for bladder preservation to avoid the 
quality of life issues that accompany radical cystectomy (9, 425). Despite its 
success as frontline immunotherapy, not all patients respond to BCG, and of 
those who do respond, over half will relapse with BCG Unresponsive NMIBC (68, 
69, 426). Unfortunately, no effective second-line therapy for BCG Unresponsive 
NMIBC exists (68-70, 425). Interferon alpha (IFNα) is a pleiotropic cytokine that 
inhibits tumor growth directly as well as indirectly through activation of the 
immune system. These multifaceted anti-tumor properties make IFNα a 
promising alternative therapy for UC. IFNα monotherapy for NMIBC was 
previously studied demonstrating good tolerability and dose-related clinical 
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effectiveness following BCG failure; however, its response durability was 
insufficient (406). With standard intravesical therapy, patients are unable to retain 
the instilled cytokine for more than 1- to 2 hours, limiting local tumor exposure.  
To overcome these limitations, intravesical gene delivery of IFNα through the use 
of adenoviral encoding IFNα (Ad-IFNα/Syn3, i.e. Instiladrin) was developed and 
early clinical trials have shown its safety and efficacy in treating BCG 
Unresponsive NMIBC (66, 67, 408). Clinical studies evaluating the use of 
intravesical Ad-IFNα/Syn3 in the bladder are ongoing (66, 67, 408).   
 Despite the clinical efficacy that has been achieved with Ad-IFNα/Syn3 in 
BCG unresponsive patients, its mechanisms of action are still not well defined in 
UC. It has been previously demonstrated that IFNα gene therapy inhibits the 
growth of human tumor xenografts by an anti-angiogenic effect and tumor 
necrosis factor-related apoptosis ligand (TRAIL)-mediated cytotoxicity (393, 403-
405, 407).  However, since these previous preclinical data were generated in 
studies of nude mice, the immune mechanisms underlying the anti-tumor activity 
of IFNα in UC have not been elucidated. It has been well described that a type I 
IFN response indirectly induces a cascade of inflammatory cytokines and 
chemokines to encourage recruitment of effector immune cells to the site of host 
distress (115). It also directly stimulates immune cells that can then further 
activate the adaptive cellular response, including memory CD8 T cells. I 
hypothesize that Ad-IFNα/Syn3 utilizes this induction of cytokines and increased 
immune cell recruitment and tumor infiltration to bestow its antitumor effects in 
patients with NMIBC. 
 In this portion of the study, I sought to identify what changes occurred in 
patients and their tumors before and after treatment with Ad-IFNα/Syn3. I wanted 
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to determine if patient tumors were more highly infiltrated with effector cells after 
treatment, and if there was a correlated relationship with the presence of 
inflammatory cytokines. Using RNA from eight Phase I Trial patients biopsied 
before and after treatment with Ad-IFNα/Syn3, I found that only 2/8 patients 
showed robust increases in expression of several T cell related genes, though 
four other patients displayed increase in at least one T cell marker gene. This 
response rate was further confirmed by IHC staining of the same patient 
specimens, in that 1/5 patients with banked tissue samples showed an increase 
in CD3+ cells following treatment with Ad-IFNα/Syn3. Utilizing urine samples from 
39 Phase II Trial patients, I identified if treatment with Ad-IFNα/Syn3 affected the 
expression of inflammatory cytokines and chemokines present in the urine, as a 
marker of the immune response, and if the presence of these cytokines was 
correlated with patient response to therapy, or clinical response (CR). I found that 
compared to pre-treatment samples, Ad-IFNα/Syn3 significantly increased the 
urinary levels of IFN and CXCL10, while also increasing TRAIL, CCL2, and IL-6 
four days after instillation with Ad-IFNα/Syn3. The increase in urinary IL-6 was 
also correlated with patient CR. 
The potential for a non-invasive biomarker detection of bladder cancer, 
and treatment response is a vigorously sought-after discovery. Urine is already 
used in urological practice for bladder cancer screening, as a secondary 
measure of malignant cell presence (cytology) (5). Utilizing urine cellular and 
molecular analysis as a predictive or prognostic marker of patient response to 
therapy represents an ideal non-invasive procedure for both patients and 
physicians. Previous studies have demonstrated that cytokines levels in urine 
can be used to determine response to BCG therapy, experimentally (82); 
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however, there is no definitive evidence of cellular biomarkers of therapeutic 
response in bladder cancer, or as a measure of response to Ad-IFNα/Syn3. I 
investigated the potential use of flow cytometry on urine samples to identify 
therapeutically-driven changes in both immune cell populations, and epithelial 
cell populations. Preliminary results revealed that it is possible to identify T cell 
populations and epithelial population in urine by flow cytometry, and that further 
investigation into more functional markers is possible. Utilizing CyTOF analysis 
may also prove to be a greater biomarker identification tool for future analysis of 
patient samples. 
 
2.2: Results 
 
2.2.1: Ad-IFNα Therapy in BCG-Unresponsive NMIBC Patients Induces an 
IFN-I Response in the Bladder and Increases Expression of T cell and 
Checkpoint Markers 
Because our previous preclinical data and Phase I trials has provided evidence 
that localized, sustained IFN could be therapeutically beneficial to BCG-
Unresponsive NMIBC patients (66, 407, 408), a Phase II trial with intravesical 
Ad-IFNα/Syn3 was conducted in 39 patients (67). To confirm that localized Ad-
IFNα/Syn3 treatment induced a sustained IFN-I phenotype, we measured 
cytokine concentrations in patient urines. Ad-IFNα/Syn3 instilled on Day 1 
significantly increased urine levels of IFNα2, CXCL10 on Day 4, with additional 
increasing trends in TRAIL, CCL2, IL-6, and G-CSF on Day 4. Significant 
increases in IFNα2, CXCL10 were still present by Day 12 (Figure 4A). 
Interestingly, the correlation of increased urinary IFNα2 and IL-6 levels from 
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Day4:Day1 (D4:D1) was significant for 13 patients who exhibited a complete 
response (CR) to Ad-IFNα/Syn3 therapy, and not significant for patients deemed 
“non-responders” (NR, 26 of 39 patients) (Figure 4B). There was also positive 
correlation for increased G-CSF levels in relation to increased IFNα2 and CR at 
Day 4, but it did not reach statistical significance (Figure 4B). There was no 
positive correlation with any other cytokine from Day12:Day1 (D12:D1) in relation 
to increased IFNα2 and CR (Figure 5). Interestingly, there are significant positive 
correlations of IFNα2 level vs. CXCL10 and TRAIL on D4:D1 for 26 of 26 patients 
who did not achieve CR, and IFNα2 vs. CXCL10, CCL2, and IL-6 on D12:D1 
from 24 of 26 of these patients (Figure 5). This may be related to a prolonged 
inflammatory response that may have deleterious effects on the patient and 
tumor as noted in other tumor models (427), but is an area for further 
investigation in NMIBC. Whole transcriptome RNAseq was conducted with 
matched pre-treatment and post-treatment tissue specimens from 8 patients with 
BCG-unresponsive NMIBC, treated with Ad-IFNα/Syn3 in the Phase I trials (66, 
408). Gene expression of PD-L1, CTLA-4, and several T cell markers were 
markedly increased in two of eight (25%) matched tumor pairs following 
treatment with Ad-IFNα/Syn3 (Figure 4C). Less dramatic upregulation of one or 
more immune biomarkers was evident in 4 of the 6 additional tumors. In addition, 
histology sections from 5 of the 8 tissue samples were also stained for CD3+ T 
cells. IHC analysis of these tumors showed an increase in CD3 T cells, localized 
in the tumor stroma, after treatment with Ad-IFNα/Syn3 in 1 of 5 samples (Figure 
4D), and undetectable changes in the CD3+ populations in the other 4 samples 
(data not shown), exemplifying IFNα’s ability to enhance intratumoral T cells with 
variability in patients.  
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More thorough molecular analysis of the 8 matched pre- and post- Ad-
IFNα/Syn3 treated patient tumor specimens from Figure 4C showed similar 
trends to the Phase II urine samples of cytokine levels, as well as other published 
knowledge of IFN-I induced gene signaling (Figure 6). Many of the IFN response 
and immune cell mediated cytotoxicity genes such as CXCL10, CCL5, CCL4, 
CCL2, PRF1, CD8A, and NFATC1 were increased in at least 4 of the 8 patient 
samples post- Ad-IFNα, mimicking characteristics of a Th1-type immune 
response. These results are also seen in the MB49 mouse tumor model, and will 
be discussed more in Chapter 4. Mirroring upregulation seen in urine samples, 4 
of 8 patients also had an increase in IL-6 gene expression. Interestingly, there 
was decreased tumor expression of genes related to fatty acid catabolism 
(FASN, ACLY, ACACA), amino acid transport, and VEGFA post-treatment, 
potentially indicating a role for IFN to decrease metabolic pathways in tumor 
inhibition. However, despite the heterogeneity of tumor response, none of the 8 
patients analyzed achieved CR at 12 months. 
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Figure 4: Effects of intravesical Ad-IFNα/Syn3 therapy on T cells and 
immune biomarkers in patients. A) Log2 observed concentration (Day 1 pre- 
Ad-IFNα therapy [D1], Day 4 post- Ad-IFNα therapy [D4] or Day 12 post- [D12]) 
of levels for cytokines indicated. Significant p-value (one way ANOVA, multiple 
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comparisons) **p<0.01 and ***p<0.001 comparing D1:D4 and D1:D12 (Error 
bars: mean ± SEM; n=39). B) Spearman correlation between log2 expression of 
IFNα2 levels and respective cytokine indicated from ratio of Day 4 post Ad-
IFNα/Syn3 to Day 1 pre-treatment in 39 patient urines. Rank coefficient r > 0.5 
indicates a positive correlation with IFNα2. Yellow boxes indicate significant p 
value (Two tailed) *p<0.05, ***p<0.001. CR=Complete Response patients; 
NR=Non-Responder patients. C) RNA from macrodissected matched tumors 
collected before or after Ad-IFNα therapy was analyzed by whole transcriptome 
RNAseq (Ion Torrent Ampliseq platform). Top panel: ratio of gene expression in 
posttreatment to pretreatment specimens. Note: gene expression increased 
significantly in two of the eight tumor pairs. Red = increased expression, green = 
decreased expression. Bottom panel: heat map displaying differential gene 
expression in each tumor pair. D) Immunohistochemistry staining of CD3+ cells in 
a patient tumor (Tumor 1 (C)), pre- and 3 months post-treatment with one dose of 
Ad-IFNα/Syn3. Scale bar = 200 µm. 
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Figure 5: Correlation of inflammatory cytokines measured in patient urine 
12 days after Ad-IFNα/Syn3 treatment. A) Spearman correlation between log2 
expression of IFNα2 levels and respective cytokine indicated from ratio of Day 12 
post Ad-IFNα/Syn3 to Day 1 pre-treatment in 39 patient urines. Rank coefficient r 
> 0.5 indicates a positive correlation with IFNα2. Yellow boxes indicate significant 
p value (Two tailed) *p<0.05, ***p<0.001. CR=Complete Response patients; 
NR=Non-Responder patients. 
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Figure 6: Ad-IFNα/Syn3 treatment increases gene expression associated 
with Th1 type anti-tumor immunity and decreases expression of metabolic 
markers. Heatmap illustrating normalized (log2) gene expression patterns from 
patients treated with Ad-IFNα/Syn3. RNA was isolated from FFPE tumor 
specimens from Phase I and Ib trials of Instiladrin (Ad-IFNα/Syn3). Whole 
transcriptome RNA sequencing was performed using the Ion Torrent 
AmpliseqRNA platform analyzed using AmpliSeqRNA plugin with the Torrent Suit 
Software, and visualized with the Broad Institute’s Morpheus software. Samples 
were hierarchical clustered according to averaged one minus pearson 
correlation.  
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2.2.2: Utilizing Urine as a Non-invasive Diagnostic and Prognostic 
Resource in the Analysis of the UC Immune and Epithelial Landscape after 
treatment with Ad-IFNα Therapy  
Previous work in UC has utilized urine as a biomarker medium for identifying 
NMIBC patient responses to BCG therapy, but it was focused on voided levels of 
inflammatory cytokines rather than measuring changes in the intra-bladder cell 
populations (82). Recent work has identified the use of urine-derived 
lymphocytes (UDLs) as a liquid biopsy tool for mapping the TME and identifying 
patients with actionable targets, like high PD-1 expression, in cases of MIBC 
(428). To this end, I hypothesized that similar strategies from these studies could 
be applied for NMIBC patients treated with Ad-IFN: to utilize flow cytometry to 
identify immune cells and epithelial cells in voided urine, with the goal of 
identifying markers of patient response to therapy, and the potential identification 
of candidates for combination therapy strategies. Using urine voided from 
patients about to undergo standard TURBT for preliminary investigation, I found 
that viable immune cells and epithelial cells could be analyzed (Figure 7A). As 
expected, cytokeratin+ cells expressed higher levels of PD-L1 than CD45+ cells 
(Figure 7B), following the results seen by many other groups. Contrary to the T 
cell focused study in MIBC, this flow analysis showed that myeloid cell 
populations as well as lymphoid cells could be easily distinguished within CD45+ 
cells (Figure 7C), which is relevant to the mechanisms of action of IFN-I. 
Interestingly, of the lymphocyte (SSC/FSC) population, roughly 50% were 
TCR+CD8-, indicating a large proportion of CD4 T cells, with only about 20% of 
CD8+ lymphocytes by comparison (Figure 7D). These results serve as a proof of 
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concept that urine can be used to measure the immune response in NMIBC 
patients. Further investigation into identifying functional aspects of these urinary 
cells, like activation status and checkpoint expression, is being performed using 
CyTOF analysis in order to develop a more comprehensive diagnostic protocol 
for liquid biopsy and detection of patient response.  
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Figure 7: Patient urine can be utilized to prospectively identify immune and 
epithelial responses to IFN therapy. Analysis of one representative urine 
sample from a patient about to undergo routine TURBT. Flow cytometry plots 
depicting A) percentage of CD45+ immune cells versus pan-Cytokeratin positive 
epithelial cells, which were more PD-L1 positive than the CD45+ cells (B). C) 
Forward scatter and side scatter immune cell classification of CD45+ population 
based on size resolution. D) Frequencies of TCR+CD8-, TCR+CD8+, and 
TCR-CD8- cells in the urine sample, gated from CD45+ lymphocyte cells. 
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2.3: Summary and Discussion 
 
There is an unmet need for effective alternative treatment options for 
patients who undergo BCG treatment, but unfortunately exhibit tumor recurrence, 
progression, or no response, and wish to preserve their bladder (avoid 
cystectomy). Type I IFNs are known to stimulate innate immune cell activation, 
enhancing recruitment of other inflammatory and effector cells, and to maintain 
and regulate these cells’ functions. It’s immune influencing actions, along with 
IFN-I’s ability to directly kill cells through TRAIL and caspase mediated apoptosis 
make the use of IFN-I effective in cancer therapy, and attractive for BCG 
unresponsive bladder cancer patients.  
In this chapter, I report that the use of Ad-IFNα/Syn3 therapy in BCG 
unresponsive NMIBC patients does induce expression of immune markers within 
tumors, and incites secretion of inflammatory cytokines and chemokines that may 
be used to encourage immune recruitment and tumor infiltration. Analyzing tumor 
specimens from Phase I Trial patients pre- and post-treatment with Ad-
IFNα/Syn3 showed increased RNA gene expression and IHC protein expression 
of T cell markers (CD3, CD4, CD8) in about 25% of patients after instillation with 
Ad-IFNα/Syn3. Delving deeper into the transcriptional changes in patient tumors 
comparing before and after treatment, I also found increased expression of 
cytokine and chemokine genes related to IFN-I response, increased expression 
of immune cell cytotoxicity genes, and decreased expression of angiogenic and 
metabolic genes related to fatty acid synthesis and amino acid transport. 
Likewise mirroring the established effects of IFN-I from literature and the results 
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seen with RNAseq here, I report that Ad-IFNα/Syn3 treatment increased 
inflammatory cytokine levels in patient urines from the Phase II Trial, most 
dramatically CXCL10, TRAIL, CCL2, G-CSF, and IL-6. Unexpectedly, I identified 
that the increase seen in IL-6 post-therapy was positively correlated with patient 
CR, inciting the need for further investigation into the role that IL-6 may play in an 
IFN-mediated antitumor response. This will be further addressed in Chapter 3.  
Angiogenesis has long been recognized as a major hallmark of cancer 
progression and its induction can lead to tumor invasion and progression. IFN-I 
pleiotropically affects multiple immune cell types, and can directly inhibit tumor 
growth by decreasing tumor vasculature, which has been previously shown in my 
group’s IFN gene therapy work (403). Recent reports show that antiangiogenic 
therapy, such as VEGF/VEGFR2 inhibitors, can up-regulate PD-L1 mediated 
immunosuppression as a strategy for immune escape (429). The use of 
antiangiogenic therapy combined with immune checkpoint blockade has been 
shown to promote higher lymphocyte infiltration and activity in several tumor 
models (429), and is currently being investigated further in clinical trials. The 
regulation of metabolic genes by IFN-I induction is an area that is currently under 
investigation. UC cells rely on glycolysis-dependent metabolism as the main 
energy source for oncogenesis, overexpressing genes such as GLUT1, HK2, and 
LDHA/B to generate products of the TCA cycle (430). Bladder cancer also 
increases expression of fatty acid synthesis metabolic genes in order to store 
surplus energy generated (431). Here I show that Ad-IFNα/Syn3 treatment 
downregulates the expression of lipid synthesis genes FASN, ACACA and ACLY, 
and amino acid transporters SNAT1 and SNAT2, potentially contributing to tumor 
inhibition. The role of IFN-I and angiogenesis and tumor cell and immune cell 
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metabolism will be discussed more in depth in Chapter 4 and the global 
discussion in Chapter 5.  
I think that Ad-IFNα/Syn3 treatment in a subset of patients (25-30%) is 
effective in preventing recurrence when i) patient tumors are initially immune 
infiltrated (by APCs), so that they can further incite an inflammatory and adaptive 
response, and when ii) Ad-IFNα is able to stimulate viral nucleic acid sensors 
(TLRs/STING), in addition to secreted TNF and IL-1, to increase production of 
IL-6. IL-6 then acts as a master regulator of immune cell recruitment, activation, 
expansion, and differentiation, and therefore promotes inhibition tumor growth by 
immune activity and surveillance (to be discussed more in depth in Chapter 3). 
However, a major aspect in patient response is if they had localized, lower 
staged tumors and had a thorough and complete TURBT prior to instillation with 
Ad-IFNα/Syn3. As evident from molecular profiling, histopathology, and diverging 
clonality, tumors are extremely heterogeneous, leading to greatly varying patient 
response. Response to therapy may be related to baseline immune infiltrate or 
tumor mutational status, if they have lost or mutated expression of IFN genes or 
other immune response genes, but more critical to the determination of response 
is the initial staging of patient tumors; that roughly 30% of patients are 
inaccurately staged (understaged) at the time of their TURBT, and so are 
recommended inappropriate therapeutic strategies (44, 432). 
Urine may also serve as a future liquid biopsy medium in NMIBC, to 
identify patients who respond to therapy or who may be candidates for 
combination immunotherapy, as I tested the possibility of immune and epithelial 
cell identification and stratification from fresh patient urines. These data suggest 
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that the use of Ad-IFNα/Syn3 therapy can potentiate immune-driven antitumor 
responses and tumor inhibition in a subset of BCG unresponsive NMIBCs. The 
finding that increased expression of T cell markers was coupled with increased 
expression of inhibitory checkpoint genes also encourages the future testing and 
use of immune checkpoint blockade and Ad-IFNα combination therapy in UC 
treatment. 
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Chapter 3: Interferon-alpha Activation inhibits growth of Murine Urothelial 
Carcinoma 
 
This work is based upon “Inhibition of urothelial carcinoma through targeted type 
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M, 
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D, 
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission. 
 
3.1: Introduction 
 
Type I interferons (IFN-I), are produced by multiple cell types following the 
stimulation of PRRs. Upon receptor activation, IFNs-I like interferon-alpha (IFNα) 
and interferon-beta (IFNβ) elicit many immunostimulatory effects including 
promotion of antigen processing, presentation, and recognition by professional 
antigen-presenting cells, and production of cytokines and chemokines, which in 
turn recruit and activate a cytotoxic T cell response against the tumor (91, 115). 
As previously mentioned, IFN-I can intervene during all stages of immunoediting, 
protecting the host against onconeogenesis and aiding the immune response to 
control existing tumors (282, 433, 434). To this point, studies have shown that 
absence of Ifnar1 encourages cellular transformation of embryonic fibroblasts 
(435), and can increase tumor burden in carcinogen-treated mice (436). 
Furthermore, many cancers have developed strategies to interfere with IFN 
actions, downregulating expression of STAT proteins and interferon regulatory 
factors and sensing genes (IRFs and ISGs) to inhibit IFN signaling and promote 
tumor progression and metastasis (437-439). However, restoration of IFN 
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signaling rescues immunosurveillance and an antitumor phenotype (397), 
underlining its crucial role in the anti-tumor immune response. 
Innate immune activation is critical to then further stimulate the antigen-
specific effector cell response. IFN-I activated CD8+ DCs are necessary to 
cross-prime tumor-specific CD8 T cells in vivo (397, 440). Preclinical studies in 
immune-poor melanoma showed that an IFN-I response induced by TLR3 
agonist poly(I:C) (polyinosinic:polycytidylic acid), a synthetic dsRNA that triggers 
PRR activation on APCs, inhibited tumor growth and increased survival alone 
and in combination with anti-PD-1 mAb checkpoint blockade (375). In this model, 
the effectiveness of poly(I:C) was particularly reliant on interferon-gamma 
positive (IFNγ+) CD8 T and NK cells (375). Further, robust tumor infiltration of NK 
cells and cytotoxic T cells correlates with spontaneous IFN-I production and good 
prognosis in melanoma patients (441, 442). IFNs-I also support the 
differentiation of monocytes into mature macrophages, and promote 
macrophage cytotoxicity and phagocytosis (121, 122). With the numerous 
targets and pathways stimulated by IFN along with the variations in tumor 
immune landscape, the mechanisms of IFN’s actions could be distinct between 
tumor types. Because of the diversity of IFN’s mechanisms in regulating the 
immune response and tumor control, elucidating IFN’s immune-mediated 
antitumor mechanism in bladder cancer is critical for interpreting patient 
response, identifying effective combination therapies, and improving the 
treatment of bladder cancer. I hypothesize that type I IFN enhances the 
activation and recruitment of effector immune cells in non-invasive bladder 
cancer, leading to robust IFN-driven antitumor responses.  
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In this portion of the study, I sought to identify the importance of specific 
immune cell populations in the IFN-driven antitumor response in bladder cancer, 
and the mechanisms by which IFN-I recruited cells to the TME. To elucidate the 
immune mechanisms underlying IFN-I’s antitumor activity in UC, I utilized local 
injection of the TLR3 agonist poly(I:C) into MB49 tumors in syngeneic C57BL/6 
mice. Indeed, I found that poly(I:C) induces an IFN-I response, inhibits tumor 
growth, and increases immune cells in murine MB49 tumors, but the antitumor 
activity was not specifically reliant on any one immune cell type, unlike the 
studies performed in melanoma (375). Interestingly however, there was an 
important anti-tumor role for IFN-I induced IL-6. I also investigated the effects of 
lentiviral-mediated IFN (LV-IFN) in the BBN-induced orthotopic mouse model 
of non-invasive bladder cancer and found LV-IFN significantly prolongs animal 
survival in comparison to lentiviral-empty vector controls (LV-CTL), and increases 
the frequency of intratumoral NK cells and CD8 T cells compared to control 
treated groups. 
 
3.2: Results 
 
3.2.1: Type I IFN Activation by Poly(I:C) Impairs MB49 Bladder Cancer 
Growth  
To determine how local induction of IFN-I impacts tumor growth in a murine 
model of bladder cancer, MB49 bladder tumor cells were implanted 
subcutaneously into syngeneic wildtype (WT) mice, followed by peritumoral 
injections of established tumors with either poly(I:C) (100 µg) or PBS every three 
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days; changes in tumor growth were monitored over time (Figure 8A). MB49 
cells were chosen owing to characteristics reminiscent of non-muscle invasive, 
non-metastatic UC (443). Treatment with poly(I:C) delayed MB49 tumor growth 
and significantly improved overall survival (Figure 8A, B). The antitumor effect of 
poly(I:C) was mediated through IFNα signaling as poly(I:C) did not induce tumor 
regression in IFNAR-/- mice (Figure 8C). Poly(I:C)-mediated tumor regression is 
likely mediated in part through direct effects of IFN-I as murine IFNα increased 
MB49 cell death in-vitro at doses over 100 IU/mL (Figure 8D). For reference, one 
dose of poly(I:C) (100 µg) induced an average ~400 pg/mL of intratumoral IFNα, 
and showed clearance from the serum in 24 hours (Figure 9A, B). Similar to the 
observed effects with Ad-IFNα/Syn3 in human urine and tumors and in immune-
poor melanoma (Figure 4A, C)(375), poly(I:C) treatment of MB49 tumors also 
led to an induction of IFN-I responsive genes IRF7 and PD-L1 compared with 
PBS-treated controls, as determined by RT-PCR (Figure 8E). Furthermore, the 
increase in IRF7 expression significantly correlated with the up-regulation of 
CD274 (PD-L1) gene expression across all tumor samples (Figure 8E). These 
data show that poly(I:C) inhibits MB49 tumor growth and prolongs survival in an 
IFNAR-dependent manner, suggesting important roles for IFNα. These data also 
confirm in the MB49 model that IFNα has direct anti-tumor action, and that IFN-I 
induces PD-L1 expression, as previously reported (444). Other murine UC cell 
lines BBN975, UPPL1541 and UPPL1595 were also used the evaluate the in 
vivo response to poly(I:C); however these tumor models exhibited spontaneous 
regression in PBS-treated controls, or inconsistent growth patterns per replicate, 
and were not deemed as viable tumor growth models (Figure 9C-E).   
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Figure 8: Poly(I:C) Treatment impairs MB49 tumor growth while 
upregulating PD-L1 expression on tumors. A) Tumor growth of subcutaneous 
MB49 tumors treated peritumorally with PBS (closed circles) or poly(I:C) (open 
square) beginning 7 days post-tumor implantation and continuing every 3 days. 
B) Kaplan-Meier analysis showing survival of mice from A. C) MB49 tumor 
growth curves of poly(I:C) or PBS-treated mice in WT or interferon alpha receptor 
knockout (IFNAR-/-) mice. D) AnnexinV/PI staining for early (Annexin+PI-) and 
late (Annexin+PI+) stage cell apoptosis of MB49 cells treated in vitro with 
increasing doses of murine IFNα. E) Correlation of relative gene expression for 
CD274 and IRF7 in control and poly(I:C) treated MB49 samples determined by 
qRT-PCR. Error bars indicate mean ± SEM; n=5 mice per group in tumor 
growth/survival and n=3 for in vitro. *p<0.05, ***p<0.001 with Student’s t test or 
Log-Rank test (Kaplan-Meier). 
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Figure 9: In vivo effects of poly(I:C) on IFN and tumor growth in BBN and 
UPPL bladder tumor models. A,B) Average concentration (pg/mL) of IFNα in 
MB49 tumors (A) and mouse serum (B) following one peritumoral injection of 
poly(I:C). C-E) Tumor growth curves of poly(I:C) or PBS treated mice in with 
either BBN975 (C), UPPL1541 (D), or UPPL1595 (E) tumors. Error bars indicate 
mean ± SEM. 
  
 86 
3.2.2: Poly(I:C) Activates Intratumoral Innate and Adaptive Immune Cells 
To investigate how poly(I:C) impacts intratumoral immune responses, we 
examined established MB49 tumors for gene expression and immune cell 
infiltration 24 hours after the prior treatment (day 14) with peritumoral poly(I:C) as 
described. Poly(I:C) significantly induced the expression of IFN-I regulated gene 
CXCL10, with other trending gene expression increases in IRF7 and the effector 
cytokines TNFA and PRF1 (perforin) (Figure 10A). We also observed a 
significant increase in the percentage of CD8 T cells and NK cell populations and 
decrease in percentage in CD4 T cells in tumor infiltrates (Figure 10B).  
Additionally, there was a consistent increase in Ly6G+ cells and accompanying 
decrease in Ly6C+Ly6G- (Ly6Chi) and Ly6C-Ly6G- (Ly6Clo) populations, though 
these changes were not statistically significant (Figure 10B, C), demonstrating 
that poly(I:C) alters the composition of intratumoral CD11b+ myeloid cell subsets.  
The CD8+ T cells in the poly(I:C)-treated tumors showed a trend in increased 
expression of IFNγ (Figure 10D), which was not statistically significant.  This 
increased IFNγ may be due to an exhausted CD8+ T cell phenotype caused by 
the IFN-I induced PD-L1 expression in the tumors (Figure 8E).  We could also 
observe similar effects in poly I:C-mediated changes in T cells in tumor tissue 
sections.  After two treatments of poly(I:C) (i.e. day 11) the total numbers of 
intratumoral CD8+ T cells increased while CD4 T cells decreased (Figure 10E). 
While these changes were not statistically significant, there was a significant 
decrease in the ratio of CD4:CD8 T cells compared with PBS-treated control 
mice (Figure 10F). Altogether, these findings suggest poly(I:C) promotes 
immune cell recruitment and/or expansion.  
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Though inconsistent for tumor growth studies, UPPL1541 and UPPL1595 
tumors were analyzed for their immune infiltration with poly(I:C) treatment as 
compared with PBS- treated controls. Mixed effects of poly(I:C) were observed in 
UPPL1541 tumors, whereby poly(I:C) increased the percentage of total 
intratumoral CD45+ cells, CD11b+Ly6G+/lo and decreased the 
CD11b+Ly6ChiLy6G- population similar to MB49, but T cells were not affected. In 
UPPL1595 tumors, which showed minimal growth inhibition from poly(I:C) 
(Figure 9), the CD45+ population decreased with poly(I:C) treatment; however, 
there were increases in the CD8 T cells, NK cells, and CD11b+Ly6G+ 
populations, similar to MB49 (Figure 11A, B). The inconsistent tumor growth 
kinetics of both UPPL tumors despite both tumor lines exhibiting similar 
molecular subtypes and mutations (445) may be a factor in their immune infiltrate 
differences, and led us to believe these models needed to be further investigated 
before use in our study.  
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Figure 10: Induction of Type I IFN by poly(I:C) enhances immune cell 
infiltration and activation. A) Relative gene expression of immune genes from 
whole tumors treated with PBS or poly(I:C); Error bars indicate mean ± SEM; 
n=4. B) Percentage of tumor infiltrating immune cells in poly(I:C)-treated tumors 
compared to PBS- treated controls at day 14, n=4. C) Flow cytometry plot 
depicting frequencies of Ly6G+, Ly6C+, and Ly6G-Ly6C- cells in a mouse from 
each group in (B) analysis, gated from CD45+CD11b+CD11c- cells. D) 
 89 
Percentage of ex-vivo CD3 stimulated IFNγ+ CD8 T cells from PBS or poly(I:C) 
treated MB49 tumors at day 14 post-implantation. E) Immunofluorescent staining 
of tumor-infiltrating CD8+ (red) and CD4+ (green) cells in PBS- or poly(I:C)-
treated tumors after 2 treatments at day 11. Image representative of 3 tumor 
samples per treatment group. Scale bar = 200μm. F) Ratio of CD4:CD8 T cells 
calculated from tumors in (E); n=3 per group.  *p<0.05, **p<0.01 with Student’s t 
test. 
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Figure 11: Poly(I:C) effects on immune cell infiltration in UPPL bladder 
tumor models. A) Percentage of tumor infiltrating immune cells in poly(I:C)-
treated tumors compared to PBS-treated controls in UPPL1595 tumor model B) 
Percentage of tumor infiltrating immune cells in poly(I:C)-treated tumors 
compared to PBS-treated controls in UPPL1541 tumor model. All results from 
Day 14 tumors. Error bars indicate mean ± SEM; n=5 per group. *p<0.05, 
**p<0.01 with Student’s t test. 
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3.2.3: IL-6 is important for Poly(I:C) Anti-tumor Efficacy, But No Specific 
Immune Cell Population is Required 
To understand the role of individual immune cell types in MB49 tumor 
progression and IFN-I-mediated antitumor responses, we examined tumor 
inhibition in mice deficient in various innate and adaptive cells. MB49 tumor 
growth in PBS-treated RAG-/- mice was increased in compared to PBS-treated 
WT mice; however, tumor growth was equivalent in poly(I:C)-treated RAG-/- and 
WT mice (Figure 12A). Similarly, depletion of T cell populations with anti-Thy1.2 
or anti-CD8 mAbs led to increased tumor growth in PBS-treated mice, but did not 
affect tumor growth in poly(I:C)-treated mice (Figure 12A). Altogether, these data 
indicate that while adaptive immune cells moderate growth of MB49 tumors in 
untreated controls, they were not critical for the poly(I:C)-mediated antitumor 
response.  While IFNs can stimulate NK cells and an IFNγ+ NK cell antitumor 
response (375), in our MB49 model, depletion of NK cells led to a reduction in 
tumor growth (Figure 12A) suggesting NK cells are pro-tumor in an untreated 
MB49 model, and that they do not play a critical role in poly(I:C)-mediated anti-
tumor activity.  To address the role of neutrophilic MDSCs and monocytes/ 
macrophages, efficacy of poly(I:C) was examined in mice depleted of Ly6G+ or 
CSFR1+ cells, respectively. Whereas depletion with αLy6G mAb had no effect on 
tumor growth in either PBS- or poly(I:C)-treated mice, depletion of CSFR1+ cells 
led to significant tumor regression in control mice but not (poly)I:C-treated mice.  
These results suggest that in this tumor model, CSFR1+ tumor-associated 
macrophages, but not Ly6G+ cells have anti-tumor activity but are not critical to 
the poly(I:C)-mediated anti-tumor response.  Interestingly, we observed a modest 
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abscopal effect following the treatment of the primary MB49 tumor with poly(I:C) 
(Figure 12B) that was abrogated when mice were depleted of CD8+ T cells 
(Figure 12C). Collectively, these findings suggest that T cell adaptive immunity is 
enhanced by poly(I:C) treatment but is not crucial for its antitumor effect.   
We also examined the roles for IL-15 and inducible nitric oxide synthase 
(iNOS) in the IFN-I response due to the central role for IL-15 in driving IFN-
mediated T cell and NK cell responses (446), and the reported use of iNOS as an 
anti-tumor effector produced by Ly6G+ neutrophils (447). In IL-15 receptor α 
deficient mice (IL15Rα-/-), both PBS and poly(I:C) treatments had similar anti-
tumor effects as in WT mice indicating a minimal role for IL-15 in the poly(I:C) 
response (Figure 13A). Drug-mediated inhibition of iNOS by N-iminoethyl-l-
lysine (L-NIL) had no effect on tumor growth when animals were treated with 
poly(I:C) however, in PBS-treated mice, inhibition of iNOS reduced tumor growth 
(Figure 13B). Because activation of innate cells can lead to production of IL-12, 
a cytokine important in the Th1 immune response and IFNγ induction (112, 448), 
we looked at the gene expression of both IL-12 isoforms and their heterodimeric 
receptor and found that poly(I:C) does significantly increase IL-12p40 and IL-
12Rb1 expression within tumors (Figure 13C).  Collectively these results suggest 
that the regulation of IL-15 or iNOS by IFN-I are not critical to the antitumor 
response of poly(I:C) in this model system, but there may be a role for IL-12 
influencing the IFN-I induced Th1 response. 
Due to the positive correlation of IL-6 with IFN and patient response 
(Figure 1), we investigated the effect of IL-6 in MB49 tumor growth. The anti-
tumor benefit of poly(I:C) was significantly inhibited in IL-6 knockout mice (IL-
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6KO), and survival of poly(I:C) treated IL-6KO mice was also significantly 
decreased as compared to poly(I:C) treated WT mice. (Figure 12D, E). In 
addition, poly(I:C) upregulated IL-6 protein as poly(I:C)-treated MB49 tumors had 
higher levels of IL-6 per mg of tumor as compared to PBS-treated controls, 
though this increase was not statistically significant (Figure 12F). As in earlier 
experiments (Figure 10B, C), poly(I:C) altered the myeloid cell landscape by 
significantly increasing the frequency of Ly6G+ cells and decreasing Ly6Chi and 
Ly6Clo cells within the tumors (Figure 12G).  Interestingly, these changes in the 
myeloid cell landscape did not occur in tumors present in the IL-6KO (Figure 
12G).  Among tumor lymphocytes, the changes in NK and T cells observed in 
poly(I:C)-treated tumors in WT mice were still intact in IL-6KO mice, though the 
poly(I:C)-mediated increase in CD8 and decrease in CD4 T cells was slightly 
impaired in IL-6KO (Figure 12H).  We also examined additional parameters of 
lymphocyte activation in the poly(I:C)-treated WT and IL-6KO mice.  Within 
secondary lymphoid tissues, poly(I:C) increased the frequency of Ki-67+ NK cells 
and CD8 T cells in spleens and draining lymph nodes (dLN) but not in tumors, 
which was abrogated in IL-6KO mice (Figure 14 A, B, data not shown).  
Similarly, there was an increased frequency of Granzyme B+ CD8 T cells in dLN 
with poly(I:C) treatment that was impaired in IL-6KO mice (Figure 14C). Overall, 
the anti-tumor response elicited by IFN-I likely represents the collective activity of 
multiple cellular components of the adaptive and innate immune response 
pathways. 
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Figure 12: Anti-tumor efficacy of poly(I:C) relies on IL-6 signaling and 
multiple immune subtypes. A) Growth of MB49 tumors treated peritumorally 
with PBS or poly(I:C)  in RAG-/- mice or WT mice depleted of specific immune 
cell populations with the indicated Ab or given control Ig. Anti-Thy1.2 mAb was 
used to deplete T cells and anti-CSFR1 mAb was used to deplete monocytes 
and macrophages; n=5 per group. B) Tumor growth of primary and secondary 
MB49 tumors in WT mice. Primary (“Established”) tumors were treated 
peritumorally with either PBS or poly(I:C) beginning 7 days post-implantation. 
Secondary (“Contralateral”) tumors were implanted 4 days after the primary 
tumors. Arrow indicates beginning of treatment. C) Tumor growth of the 
contralateral tumor similar to (B) in CD8 depleted mice. D) Growth of MB49 
tumors treated peritumorally with PBS or poly(I:C) in IL-6 knockout (IL-6KO) or 
WT mice. E) Kaplan-Meier analysis of survival of mice from D; n=5. F) Average 
concentration of IL-6 (pg/mL) per tumor weight (mg) in MB49 tumors from Day 14 
tumors treated with either poly(I:C) or PBS; n=5 per group. G,H) Frequency 
(percentage) of Ly6G+, Ly6Chi, and Ly6Clo cells (G) and frequency of NK, CD4, 
CD8 T cells from MB49 tumors of WT and IL-6KO mice treated with PBS or 
poly(I:C) among gated CD45+CD11b+ cells and CD45+ cells, respectively; n=5. 
Error bars indicate mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
with Student’s t test. 
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Figure 13: Anti-tumor efficacy of Poly(I:C) is not mediated by IL-15 or iNOS. 
A) MB49 tumor growth curves of poly(I:C) or PBS treated mice in WT or IL-15 
receptor alpha knockout mice (IL15Rα-/-). B) MB49 tumor growth of mice treated 
with iNOS inhibitor L-NIL in combination with peritumoral PBS or poly(I:C). For all 
groups, n=5. Error bars indicate mean ± SEM. C) Log2 gene expression of IL-12 
subunits and receptor subunits from MB49 tumors after 3 treatments of PBS or 
poly(I:C); n=4 per treatment group, error bars indicate mean ± SEM. *p<0.05 with 
Student’s t test. 
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Figure 14: Poly (I:C)-mediated lymphocyte activation is impaired in the 
absence of IL-6.  A,B) Percentage of Ki-67+ immune cells in either spleen (A) or 
tumor draining lymph node (dLN) (B) of poly(I:C)-treated WT and IL-6KO mice 
compared to PBS- treated respective controls at day 14, gated from CD45+ cells; 
spleen n=5, dLN n=3. D) Percentage of GZMB+CD44+ CD8 T cells in spleen and 
tumor dLN of poly(I:C)-treated WT and IL-6KO mice compared to PBS- treated 
respective controls at day 14, gated from CD45+CD8+ cells; spleen n=5, dLN 
n=3. Error bars indicated mean ± SEM. *p<0.05, ***p<0.001 with Student’s t test. 
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3.2.4: LV-IFN promotes survival and increased intratumoral immune 
effector cells in BBN-induced murine bladder tumors 
To determine how local production of IFN-I by viral-mediated intravesicle 
instillation impacts tumor inhibition and immune cell responses in the bladder, I 
examined animal survival and tumor-immune infiltrate in the N-butyl-N-(4-
hydroxybutyl)-nitrosamine (BBN) carcinogen-induced murine orthotopic bladder 
cancer model (Figure 15). Following 60 days of BBN treatment, in which mice 
were deemed to have non-invasive tumors or CIS (Figure 15A), mice were 
intravesically instilled weekly with LV-IFN or LV-CTL. Differences in tumor 
growth were difficult to monitor, as ultrasound imaging was not sensitive enough 
to detect weekly changes; however, treatment with LV-IFN significantly 
prolonged survival in comparison to LV-CTL (Figure 15B). Investigating the 
effect of LV-IFN on the immune infiltrate of BBN-induced tumors, I observed an 
increase in the frequency of CD8 T cells in both lentiviral-vector treated groups 
as compared to PBS controls, but this increase was not statistically significant 
(Figure 15C).  Unlike the MB49 model, there was no increase in Ly6G+ cells and 
accompanying decrease Ly6C+ populations (Figure 15C), suggesting that LV-
IFN doesn’t preferentially induce a Ly6G+ cell response like poly(I:C). 
Altogether, these findings suggest that like poly(I:C) in MB49 tumors, LV-IFN 
treatment promotes survival and immune cell recruitment and/or expansion in the 
BBN-induced tumor model. However, it is important to keep in mind that the 
inherent differences between the MB49 and BBN-induced tumors brought on by 
their origins, such as their mutational burden and pathology, may be linked to the 
diversity in their immune landscapes and responses to IFN-I, as seen here. 
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Figure 15: LV-IFN improves survival and increases intratumoral immune 
cells in BBN-carcinogen induced bladder cancer. A) Experimental strategy for 
development of BBN-induced bladder cancer mouse model. After 2 months, mice 
began intravesical instillation with lentiviral-control vector (LV-Control) or 
lentiviral-IFN vector (LV-IFN). B) Kaplan-Meier analysis of survival of mice 
treated with either LV-Control of LC-IFN. C) Frequency (percentage) of NK, 
CD4, and CD8 T cells from the SSC/FSC CD45+ lymphocyte population, 
frequency of CD11b+ cells from the SSC/FSC myeloid designated population, 
and Ly6G+ and Ly6C+ cells among gated CD11b+ population from bladder of 
BBN-tumor induced mice treated with LV-Control or LV-IFN; n=5. Error bars 
indicate mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 with Student’s t test or Log-
Rank test; These experiments were performed in part by Dr. Sharada Mokkapati. 
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3.3: Summary and Discussion 
 
The use of type I IFN as a cancer therapy has had mixed successes due 
to its route of administration and short half-life. Despite early therapeutic 
shortcomings, IFN-I has been shown to have direct tumor killing ability by the 
induction of TRAIL and apoptosis signaling, and it can incite an inflammatory 
response, including maturation and activation of innate and adaptive immune 
cells, promoting their migration to the tumor. Because of the variety of IFN’s 
mechanisms in controlling tumor growth and the immune response across 
different tumor types, determining IFN’s immune-mediated antitumor 
mechanism in bladder cancer is critical for interpreting patient response, 
identifying effective combination therapies, and improving patient outcomes.  
In this chapter, I examined the immune mechanisms behind IFN-I-
mediated anti-tumor responses in murine models of UC. I found that IFN-I 
induction by poly(I:C) in MB49 tumors inhibits tumor growth, increases longevity, 
and activates both the innate and adaptive immune systems. Poly(I:C) increased 
the intratumoral frequencies of CD8, NK, and Ly6G+ cells, and decreased the 
frequencies of CD4 and Ly6C+Ly6G- cells, but it’s antitumor efficacy was found to 
not be dependent on any one of these individual cell types. The poly(I:C) 
mediated tumor inhibition was, however, found to be dependent on functioning 
IL-6 signaling, which was necessary for higher levels of intratumoral Ly6G+ and 
CD8 cells, and proliferation and activation of NK cells and CD8 cells in secondary 
lymphoid organs. This IL-6 dependence mirrors the positive correlation of IL-6 
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urinary cytokine expression with patient response (CR) to Ad-IFNα/Syn3 therapy. 
I also found that LV-IFN similarly prolonged survival and increased intratumoral 
T cell and NK cell populations in the BBN-induced bladder cancer mouse model. 
Treatment of MB49, BBN, and UPPL tumors with poly(I:C) or LV-IFN 
resulted in an IFN-I induced infiltration of highly diverse immune populations 
representing a multifaceted pro-inflammatory anti-tumor phenotype, contrary to 
the defined dependence of tumor-inhibitory poly(I:C) on specific immune subsets 
in studies performed in melanoma (18).  Previous studies in experimental bladder 
cancer have focused on the necessity of the T cell infiltration for an anti-tumor 
response, and thus have relied on T cell checkpoint targeted immunotherapy 
(443, 449, 450). However, the importance of both lymphoid and myeloid cell 
types in the anti-tumor response in my MB49 studies indicates that focusing on a 
single subset of effector cells may limit the insights to be gained.  
I also found an important role for IL-6 signaling in the type I IFN-driven 
MB49 tumor inhibition as well as in patients treated with Ad-IFNα/Syn3. IL-6 has 
been shown to have a dichotic role, acting as both a pro-inflammatory and an 
anti-inflammatory cytokine, in cancer as well as autoimmune diseases, providing 
an activation signal to immune cells that left unchecked has the potential to 
produce deleterious effects (451). As previously mentioned, IL-6 regulates innate 
and adaptive immune defense in a pro-inflammatory capacity by inducing the 
acute phase response, hematopoiesis (granulopoiesis), B cell differentiation 
and antibody production, and recruitment of neutrophils and other immune 
cells by promoting increased expression of trafficking chemokines CCL2, 
CXCL5, CXCL6 and adhesion molecules CD62L, ICAM-1, and VCAM-1(130, 
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131, 139). It also promotes the activation and expansion of T cells, and 
differentiation of CD4 T cells into i) TFH cells to aid in B cell antibody switching 
and ii) pro-inflammatory Th17 T cells, and can suppress inducible CD4 Treg 
formation and function (132-134, 139). Anti-inflammatory effects of IL-6 include 
a role in wound healing and liver regeneration (137), and regulation of the 
production of pro-inflammatory cytokines TNF, GM-CSF, IFN, MIP-2 in acute 
inflammation to prevent deleterious immunopathology and promote 
inflammatory resolution (138, 452).  
In the MB49 model treated with poly(I:C) and in NMIBC patients treated 
with Ad-IFN, I believe IL-6 is the master key in regulating the multifocal 
immune cell anti-tumor response by increasing chemokine production for 
immune recruitment, particularly the Ly6G+ cell recruitment, and increasing NK 
and T cell proliferation and activation, summarized in Figure 16. Backing this 
conclusion, it has been shown that IL6-/- neutrophils have impaired respiratory 
burst and degranulation, and also have impaired leukocyte apoptosis, affecting 
the transition into adaptive immunity (453). IL-6 also increases CD8 cytotoxic 
activity in vitro (134), supporting my observation that IL6-/- mice had decreased 
GZMB+ CD8 T cells in the draining lymph node. There are many other effects of 
IL-6 on immune cells that I did not thoroughly investigate here, such as the 
propensity and role of CD4 Th17 and Treg cells in the MB49 model, and how IL-6 
may affect macrophage activity and monocyte differentiation which was just 
touched upon by CSFR1 depletion in WT mice (Figure 12A). I would speculate 
that IL-6 driven differentiation and activation of Th17 cells and macrophages also 
contributes to the IFN-I antitumor response in bladder cancer by further 
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promoting neutrophil recruitment, T cell priming, and pro-inflammatory cytokine 
production (454). The potential link of IL-6 to type I IFN-driven anti-tumor 
responses in both murine models and in patients sparks the need for further 
investigation of the role of this cytokine in IFN-I treated bladder cancer.  
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Figure 16: Suspected role of IL-6 signaling in UC. Stimulated by inflammatory 
cytokines, TLR signaling and stress, IL-6 is produced by almost all stromal and 
immune cells. It goes on to activate STAT3 signaling and regulate T cell 
differentiation (promotes CD4 Th17, inhibits CD4 Treg), proliferation, and 
activation (GRZB+). IL-6 is also important in the recruitment of innate and 
adaptive immune cells through induction of the acute phase response (secretion 
of inflammatory cytokines) and stimulation of chemokine production from stromal 
cells. I show that IL-6 signaling is needed to increase (Ki67+) NK cell proliferation 
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in secondary lymphoid tissues. Not depicted here: IL-6 also controls B cell 
survival, expansion and maturation (Ab production), but I did not examine the B 
cell compartment in MB49/BBN tumors.  
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Chapter 4: Combination Therapy of Interferon-alpha Activation with T-Cell 
Checkpoint Modulation Prolongs Survival 
 
This work is based upon “Inhibition of urothelial carcinoma through targeted type 
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M, 
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D, 
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission from 
Oncoimmunology.  
 
4.1: Introduction 
 
In addition to its roles in promotion of DC, macrophage, T cell, and NK cell 
maturation, migration/taxis, and function (118-120, 391, 392), and direct cell 
killing through TRAIL-mediated apoptosis (393), IFNα has been shown to 
increase programmed death ligand-1 (PD-L1) and programmed cell death 
protein-1 (PD-1) expression on tumor and immune cell subsets (395, 444). 
Induction of PD-L1 and PD-1 has led to adaptive immune resistance by 
promoting T cell exhaustion and immune evasion (244, 289, 395, 444). This 
consequence may decrease the effectiveness of IFNα as a monotherapy, but 
suggests that IFNα use in combination with immune checkpoint blockade may 
lead to improved therapeutic outcomes. Use of anti-CTLA-4 and anti-PD-1/PD-L1 
checkpoint blockade therapies have produced clinical responses and tumor 
regression across many solid and hematologic cancers, often with durable or 
indefinite results, by increasing absolute lymphocyte counts and T cell activation, 
inducing expression of ICOS, and depleting Treg populations (90, 455). However, 
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refractory disease and acquired resistance mechanisms via immunoediting are 
major problems of checkpoint blockade therapy (455). 
Indeed, acquired resistance to PD-1/PD-L1 blockade is associated with 
loss of genes encoding IFN receptor-associated Janus kinases, JAK1 and JAK2 
(288, 456). Additionally, non-responders to checkpoint inhibitors such as anti-
Cytotoxic T-Lymphocyte Antigen-4 (anti-CTLA-4) possess tumors with co-
deletions of IFNα and IFNβ genes on chromosome 9p21 and defects in IFN 
pathway genes (288). These findings highlight the potential exploitable 
relationship between not only PD-1/PD-L1 and IFNs, but other checkpoint 
molecules as well. I hypothesize that though IFN-I induces expression of immune 
evasion markers like the PD-1/PD-L1 axis, combined use of IFN and anti-PD-1 
checkpoint inhibition therapy will synergistically increase the antitumor effects 
against bladder cancer seen with IFN alone, via increases in immune 
recruitment and activation and decreased tumor growth, improving clinical 
benefit. 
 Understanding the relationship between IFNα and immune checkpoint 
inhibition is important for interpreting immunotherapy resistance and improving 
the treatment of UC and other solid tumors. In this portion of the study, to test 
therapeutic synergism, I utilized local poly(I:C) administration in combination with 
systemic anti-PD-1 mAb therapy in C57BL/6 mice with MB49 tumors. I found that 
their combined use reduced tumor burden comparably to single-agent poly(I:C) 
treated mice, but combination treatment significantly prolonged animal survival. 
However, no significant difference was found in the intratumoral immune cell 
populations between single agent and combination treated tumor groups. 
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Investigating the differences between either poly(I:C) or anti-PD-1 mAb alone, 
and combination treatment of MB49 tumors on a molecular level, combination 
treatment comparatively decreased tumor vasculature and angiogenesis, and 
increased expression of genes associated with metabolism, extracellular matrix 
organization, and ERK/MAPK signaling. I also compared the molecular changes 
seen in PBS-, poly(I:C)-, anti-PD-1 mAb-, and combination-treated MB49 tumors 
to pre- and post- Ad-IFN treated patient tumor samples (from Figure 6), and 
found that signaling pathway genes associated with poly(I:C) treatment, such as 
IFN response and cytotoxicity are similarly upregulated, and metabolic pathway 
genes are similarly downregulated to those in patients post-Ad-IFN treatment, 
but not with anti-PD-1 or combination treatments.  
 
4.2: Results 
 
4.2.1: Combination Treatment with Anti-PD-1 mAb and Poly(I:C) Reduces 
Tumor Burden and Prolongs Survival 
Given that IFN-I signaling induces expression of checkpoint markers such as PD-
L1 (Figure 4, 8) which may lead to decreased effector T cell function (244, 289, 
395, 444), we reasoned that therapeutic blockade of the PD-1/PD-L1 pathway 
could further enhance the anti-tumor efficacy of poly(I:C). Subcutaneous MB49 
tumor-bearing mice were treated with poly(I:C) and a PD-1–blocking mAb either 
as monotherapies or in combination (Figure 17A). Tumor growth was measured 
overtime until mice became moribund. Treatment with both single-agent poly(I:C) 
and combination therapy [poly(I:C) with anti-PD-1 mAb] significantly repressed 
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tumor growth compared with anti-PD-1 mAb alone and IgG/PBS-treated controls 
(Figure 17B). However, we observed no significant difference in tumor growth 
inhibition between poly(I:C) monotherapy and combination therapy. Nonetheless, 
combination therapy significantly prolonged survival compared with poly(I:C) 
alone (Figure 17C) demonstrating IFN-I can work with checkpoint blockade for 
enhanced efficacy. In 16 day-old MB49 tumors treated with either single agent or 
combination therapy, combination treatment significantly increased the level of 
intratumoral Ly6G+ cells in comparison to poly(I:C) alone, which may contribute 
to the difference in survival, but there was no significant difference between the 
CD8, CD4, NK, and Ly6C+ immune cell populations between poly(I:C) and 
combination treatment groups (Figure 18). However, this observed result was 
only from one experimental analysis, and would need to be consistently repeated 
for a more definitive conclusion. 
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Figure 17: Blockade of PD-1/PD-L1 pathway reduces tumor burden and 
prolongs survival in poly(I:C) treated mice. A) Experimental strategy for 
combination therapy for s.c. engrafted MB49 tumors for peritumoral poly(I:C) and 
anti-PD-1 mAb (i.p.). B) Averaged tumor growth of mice treated with either single 
agent poly(I:C) or anti-PD-1 mAb, poly(I:C) plus anti-PD-1 mAb, or control IgG 
plus PBS or control observation. C) Kaplan-Meier analysis of survival of mice 
from C. Error bars indicate mean ± SEM, n=10; *p<0.05, **p<0.01, ***p<0.001 
with Student’s t test or Log-Rank test; Graphs representative of 3 separate trials. 
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Figure 18: Poly(I:C) and anti-PD-1 mAb combination therapy increases 
intratumoral Ly6G+ cells in MB49 tumors as compared to poly(I:C) alone. 
Percentage of tumor infiltrating immune cells in poly(I:C)-, anti-PD-1 mAb-, and 
poly(I:C) + anti-PD-1 mAb- treated MB49 tumors compared to IgG + PBS- 
treated control MB49 tumors at Day 16. CD8, CD4, and NK cells are gated from 
CD45+ SSC/FSC designated lymphocytes; Ly6G and Ly6Chi cells are gated 
from lineage negative (TCR-CD19-NK1.1-), CD11b+ cells. aPD1, anti PD-1 
mAb; Combo, combination poly(I:C) + anti-PD-1 mAb treatment. Error bars 
indicate mean ± SEM, n=5; *p<0.05, **p<0.01, ***p<0.001 with Student’s t test. 
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4.2.2: Combination Treatment Induces MAPK Signaling, Metabolic 
Pathways, and Reorganization of Tumor Microenvironment 
To examine potential molecular changes between treatment groups, 
comprehensive gene expression analysis was performed via RNA sequencing 
and GSEA on total mRNA collected from day 17 tumors treated with PBS, 
poly(I:C), anti-PD-1 mAb, or in combination. GSEA of the RNAseq data from the 
poly(I:C), anti-PD-1 mAb, and the combination showed enrichment in viral stress 
response, IFN signaling, cytokine signaling pathways, and innate immune 
response in comparison to control tumors (Table 2). However, the single agent 
anti-PD-1 mAb as well as the combination treatment also enriched pathways 
promoting cell migration, differentiation, proliferation, and survival through MAPK, 
MEK/ERK and AKT signaling (Table 2). Combination treatment up-regulated 
additional pathways related to collagen formation, extracellular matrix formation, 
and cell-cell signaling (Table 2).  Comparing the poly(I:C) and combination 
treated groups to each other, metabolic pathways for glucokinase regulation and 
fatty acid oxidation (FAO) and synthesis were enriched in the combination group 
(data not shown).   
Looking more closely at effects on individual genes, we found numerous 
genes related to IFN pathway signaling (Figure 19A), as well as adaptive and 
innate effector cell cytotoxicity such as Granzyme B (GZMB) were significantly 
increased in the poly(I:C) treated group, and more modestly increased in the anti-
PD-1 mAb and combination treated groups, in comparison to control IgG/PBS 
treated tumors (Figure 19A, B). As expected, there were also increases in gene 
expression for immune suppressive molecules in poly(I:C), anti-PD-1 mAb, and 
combination treated mice, including ARG1 and ARG2 (Arginase 1 and 2), IDO, 
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and CD274 (PD-L1) (data not shown). Exploring the GSEA-identified upregulated 
metabolic pathways, we found poly(I:C) induced expression of glucose 
transporter GLUT1, and all treatment groups increased expression of glycolysis 
enzymes HK2 and GCK in comparison to PBS/IgG control (Figure 19A, B). 
Interestingly, while poly(I:C) decreased tumor expression of genes related to fatty 
acid catabolism and synthesis such as FASN, ACACA, and ACLY in comparison 
to PBS control, anti-PD-1 mAb and combination treatment significantly rescued 
their expression (Figure 19A, B). We also observed increased MAPK signaling 
genes in all treated groups in comparison to control, and decreased expression 
of VEGF, MMP9, and EGFR. Similar trends in gene expression were also 
observed in the 8 matched pre- and post- Ad-IFNα/Syn3 treated patient tumor 
specimens from Figure 6, despite none of the patients reaching CR. To further 
investigate the decreased expression of angiogenesis markers seen in the 
RNAseq of MB49 tumors treated with poly(I:C), anti-PD-1 mAb, or combination, 
we performed IHC staining of CD31 on tumors from each treatment group taken 
at their end point (day 38) (Figure 19C). Poly(I:C) alone and in combination with 
anti-PD-1 mAb significantly decreased microvessel density (MVD) compared to 
control PBS/IgG treated tumors by ~50% (Figure 19D). Thus, while IFN-I has 
significant anti-tumor action, combination therapy with checkpoint blockade 
activates additional pathways regulating the increased stromal influx and 
reorganization of ECM, inhibition of angiogenesis, glycolysis and fatty acid 
catabolism, and increased MAPK/ERK/AKT signaling that may be related to 
prolonged survival. 
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Table 2: Summary of the Reactome Gene sets enriched in treatment groups: Name, Process Category, 
Description, Number of genes involved, NES 
Treatment Reactome Name 
Process 
category Description 
Number 
of genes NES` 
poly(I:C) Activation of genes by ATF4 signaling 
transcription factor; 
response to ER stress, 
PERK signaling 21 1.89 
 
PERK regulated gene 
expression signaling 
integrated stress 
response and protein 
folding 24 1.79 
 Interferon γ signaling immune type II IFN signaling 42 1.75 
 Toll receptor cascades immune 
TLR stimulated immune 
signaling 109 1.65 
 
Class I MHC mediated 
antigen 
processing/presentation immune 
innate and adaptive 
immune recognition of 
antigen 221 1.59 
 
TRAF6 mediated IRF7 
activation immune viral, IFN response 20 1.58 
 
Trans golgi network vesicle 
budding pathway 
secretory pathway for 
synthesized proteins 52 1.58 
 ER Phagosome pathway pathway cell death pathway 53 1.56 
 
Latent infection of homo 
sapiens with mycobacterium 
tuberculosis immune innate immune effectors 30 1.55 
 
Antigen processing cross 
presentation immune antigen presentation 65 1.55 
 
Antigen presentation, folding, 
assembly, and peptide 
loading of Class I MHC immune antigen presentation 15 1.54 
* Innate immune system immune innate immune signaling 201 1.68/1.58 
* IL-1 signaling immune 
damage associated 
molecular pattern 
(DAMP), inflammatory 
signaling 37 1.63/1.68 
* 
Nucleotide binding domain 
Leucine rich repeat 
containing receptor NLR 
signaling pathways signaling 
NOD-like receptor 
signaling, viral response 42 1.59/1.54 
* NOD1/2 signaling pathway immune 
NOD-like receptors for 
antigen recognition, 
inflammatory signaling 29 1.58/1.71 
+ Interferon signaling immune interferon signaling 121 
1.88/1.77
/1.7 
+ Interferon α,β signaling immune type I IFN signaling 43 
1.77/1.65
/1.62 
+ 
Cytokine signaling in Immune 
system immune cytokine signaling 224 
1.75/1.77
/1.52 
+ 
Antiviral mechanism by IFN 
stimulated genes immune 
antiviral stress response 
through IFN 62 
1.72/1.99
/1.97 
+ 
Negative regulators of RIG-I 
MDA5 signaling immune 
viral recognition receptor 
sensing 28 
1.69/1.58
/1.55 
      
 α-PD-1 mAb 
Interaction between L1 and 
ankyrins 
developm
ent cell adhesion molecules 20 1.67 
 Signaling by ILs immune inflammatory signaling 102 1.57 
 
SEMA4D in semaphorin 
signaling signaling 
CD100 binding to CD72 
to activate immune cells 28 1.55 
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 Myogenesis 
developm
ent muscle differentiation 26 1.54 
 
Platelet aggregation plug 
formation 
developm
ent 
platelet aggregation, 
hemostasis 35 1.54 
 
JNK, C-JUN Kinases 
phosphorylation and 
activation mediated by 
activated human TAK1 signaling 
JNK signaling; stress 
response, IRF3, T cell 
differentiation and 
apoptosis 16 1.53 
 
MAP Kinase activation in TLR 
cascade signaling 
MAPK signaling in stress 
response 49 1.52 
# 
SEMA4D induced cell 
migration and growth cone 
collapse signaling 
CD100 binding 
activation, immune 
activation by CD72 24 1.64/1.63 
# 
SHC1 events in ERBB4 
signaling signaling 
MAPK signaling, cell 
migration, survival, 
differentiation 19 1.6/1.63 
# 
MAPK targets/Nuclear events 
mediated by MAP Kinases signaling 
proliferation, 
differentiation, survival 30 1.56/1.45 
# Signaling by PDGF signaling 
angiogenesis, 
proliferation, migration 115 1.52/1.45 
      
poly(I:C) + α-
PD-1 mAb Pre notch processing in golgi signaling 
maturation of notch 
receptor  16 1.71 
 Muscle contraction 
developm
ent muscle contraction 46 1.56 
 
Activation of chaperone 
genes by XBP1S signaling 
cellular response to ER 
stress, UPR 41 1.55 
 Collagen formation 
developm
ent collagen formation 53 1.54 
 
Extracellular matrix 
organization 
developm
ent 
extracellular matrix 
organization 76 1.54 
 Gap junction trafficking signaling cell-cell communication  24 1.52 
 
Chondroitin sulfate dermatan 
sulfate metabolism metabolic 
glycosaminoglycan/prote
oglycan; anti-
inflammatory  47 1.5 
 
Chondroitin sulfate 
biosynthesis metabolic 
proteoglycan; anti-
inflammatory  19 1.5 
 ERK/MAPK targets survival  
proliferation, 
differentiation, survival 21 1.47 
 Circadian clock metabolic 
circadian rhythm, 
metabolic pathways 49 1.46 
  Gap junction assembly signaling cell-cell communication  16 1.45 
* Pathways are up-regulated in both poly(I:C) 
and anti-PD-1 treated groups     
# Pathways are up-regulated in both anti-PD-1 and 
combination poly(I:C)+anti-PD-1 treated groups    
+ Pathways are up-regulated in poly(I:C), anti-PD-1, and 
combination treated groups    
` Normalized enrichment score (NES); up-regulated 
pathways defined as (NES) > 0    
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Figure 19: Poly(I:C) and anti-PD-1 mAb combination therapy promotes gene 
expression associated with survival, metabolism, and Th-1 type anti-tumor 
immunity and decreases angiogenesis. A) Heatmap illustrating normalized 
(log2) gene expression patterns from MB49 whole tumor lysates treated with 
either PBS+IgG Ab, poly(I:C), anti-PD-1 mAb, or poly(I:C)+anti-PD-1 mAb; RNA 
was isolated from tumors 17 days post-implantation (4 treatments) (Figure 4A). 
Each column represents one mouse. B) Average relative gene expression of 
indicated genes associated with effector function, fatty acid oxidative metabolism, 
glycolysis, and AKT, MEK/ERK pathway from the 4 treatment arms (n=4 per 
group). C) IHC staining for CD31 (PECAM-1) in end point tumors from 38 days 
post-implantation (11 treatments); Scale bar = 100µm. Image is representative of 
3 tumors per treatment group. D) Quantified microvessel density (MVD) 
averaged from IHC CD31-stained tumors (6C) (n=3 per group). All values 
normalized by DeSeq and log2 transformed (heatmap). Error bars indicate mean 
± SEM, n=4 per group. *p<0.05, **p<0.01 with Student’s t test. 
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4.3: Summary and Discussion 
 
IFN-I, while capable of inhibiting tumor growth and inciting an immune 
response to aid in host defense, intrinsically increases mechanisms of tumor 
resistance by upregulating expression of immune checkpoint markers like PD-L1 
on cancer tissue and surrounding cells of the TME. Immune inhibitory 
checkpoints are important in regulating autoimmunity and collateral tissue 
damage in an immune response, but in the context of cancer, can inhibit effector 
T cell responses by inhibiting proliferation and IL-2 secretion and promoting T cell 
exhaustion and anergy (257). Despite these mechanisms of adaptive immune 
resistance, therapeutic antibody-mediated blockade of inhibitory checkpoints has 
produced tumor regression and durable patient responses (415). Because of the 
inherent PD-1/PD-L1 pathway tumor evasion strategy induced by IFN treatment, 
I explored the potential of IFN-I therapy combined with PD-1pathway checkpoint 
inhibition to provide synergistic treatment benefit to MB49 tumors.  
In this chapter, I show that combination IFN-I and anti-PD-1 mAb 
checkpoint blockade reduces tumor burden and significantly prolongs survival, 
though there is no significant difference in tumor reduction between poly(I:C) 
alone and combination treatment. Similarly, there were no significant differences 
in the frequencies of CD8, CD4, NK, Ly6G, or Ly6Chi cells between poly(I:C), 
anti-PD-1, or combination treatment, although there was an increasing trend in 
Ly6G cells with corresponding decrease in Ly6Chi cells with combination therapy 
that was consistently reproducible. Molecular profiling of the differently treated 
tumors revealed that poly(I:C), anti-PD-1, and combination treatment all 
increased expression of genes related to antiviral response, interferon, and 
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cytokine signaling, and decreased genes related to angiogenesis and 
vascularization (CD31 IHC). Interestingly combination treatment enriched gene 
signatures related to ECM organization and collagen formation, possibly alluding 
to an increased stromal infiltrate. Further clarification of which GSEA analyzed 
pathways are conserved or different between each treatment group is described 
in Figure 20A. I also compared the molecular changes seen in PBS-, poly(I:C)-, 
anti-PD-1 mAb-, and combination-treated MB49 tumors to pre- and post- Ad-
IFN treated patient tumor samples (from Figure 6). I found that signaling 
pathway genes, such as IFN response and cytotoxicity related CXCL9, CXCL10, 
TRAIL, CCL2, CCL5, CD8, and PRF1 are similarly upregulated in poly(I:C)-, anti-
PD-1 mAb-, and combination-treated MB49 tumors, like in the post-Ad-IFN 
specimens; however, metabolic pathway genes such as FASN, ACLY, and 
ACACA, are only similarly downregulated with single agent poly(I:C)/IFN-I 
treatment, not with anti-PD-1 or combination treatments.  
My initial hypothesis that combined usage of IFN-I therapy with anti-PD-1 
checkpoint blockade would synergize to provide greater clinical benefit was not 
herein definitively proven. While I did see a difference in animal survival, there 
were no clear factors as to how combination therapy provides greater clinical 
benefit, based on lack of significant differences in tumor burden, no major 
differences in the tumor-immune infiltrate, and RNA sequencing analysis shows 
stronger upregulation of IFN response and immune cytotoxicity genes in poly(I:C) 
alone than other treatment groups. Overstimulation of inflammatory pathways 
has been shown to produce a “cytokine storm” that can result in significant 
pathology and ultimately death (457, 458). In a model of viral infection and 
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Figure 20: Summary: Gene expression pathways regulated by single and 
combination treatment of MB49 tumors. A) Enriched signaling pathways 
identified by GSEA analysis in MB49 tumors treated with either poly(I:C), anti-
PD-1 mAb, or poly(I:C)+anti-PD-1 compared to PBS/IgG control. B) Canonical 
pathways upregulated or downregulated in poly(I:C) and poly(I:C)+anti-PD-1 
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mAb treated tumors identified by IPA analysis. ISGs, interferon sensing genes; 
PDGF, platelet derived growth factor; LXR/RXR, liver X receptor/retinoid X 
receptor; PRRs, pattern recognition receptor; IRF, interferon regulatory factor; 
THOP, thimet oligopeptidase; GPCR, g protein coupled receptor; MMPs, matrix 
metalloproteinases. 
  
 122 
poly(I:C), mice lacking an adaptive immune response (nude and Rag-/- mice) 
had higher mortality rates after virus/poly(I:C) dosage due to higher abundances 
of proinflammatory cytokines TNF and IFNγ in the serum days after infection 
compared to WT mice (459). Addition of T cells to the non-T cell, TLR3-
stimulated system efficiently prevented this cytokine surge, suggesting that active 
T cell monitoring is necessary to temper an innate response. One hypothesis for 
why combination treated mice had improved survival over poly(I:C) alone is that 
the addition of anti-PD-1 mAb is able to reactivate T cells (particularly Tregs) that 
have become exhausted from IFN-I stimulated PD-L1 expression, which results 
in tempering of the innate cytokine response invoked by IFN-I signaling. This 
warrants future analysis in the MB49 model. 
GSEA and RNAseq analysis of MB49 tumors treated with either single 
agent poly(I:C), anti-PD-1 mAb alone, or combination therapy showed anticipated 
enrichment in genes and pathways related to IFN induction, viral stress 
response, cytokine production and innate immune activation, as well as MAPK 
and ERK signaling in comparison to PBS treated control tumors. MAPK/ERK 
signaling traditionally is associated with cell survival, proliferation, and 
differentiation. However, there is evidence that ERK signaling has pro-apoptotic 
functions in response to damage stimuli (460), and this mechanism may add to 
the immune component of the IFN-I anti-tumor response, providing further 
survival benefit demonstrated in this study.  
Previously published studies identified that blockade of the PD-1/PD-L1 
axis reverses T cell exhaustion, re-inducing glycolysis and anabolic metabolism 
to produce a more active state (317, 461). In this work, I found that poly(I:C), 
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anti-PD-1 mAb, and combination treated groups have increased levels of 
enzymes involved in glycolysis and the TCA cycle (GLUT1, HCK, GCK). 
Interestingly, I also found in comparison to poly(I:C) treatment alone, the addition 
of anti-PD-1 mAb enriched for extracellular matrix reorganization, collagen 
formation, and increased genes related to FAO and fatty acid synthesis such as 
FASN, ACLY, and ACACA. Increasing mitochondrial FAO metabolism in T cells 
has been shown to favor the formation of long-lived memory T cells (462, 463). 
However, the whole tumor RNA analyzed here is likely more reflective of the 
tumor genome than the immune microenvironment. Since and fatty acid 
synthesis and glycolysis are necessary for cellular growth and proliferation (464), 
this analysis suggests that combination treated tumors are upregulating 
pathways of proliferation in the tumor cells while simultaneously inhibiting tumor 
growth. Upregulation of expression of genes involved in ECM remodeling and 
mesenchymal transition has been shown to be a marker of resistance to anti-PD-
1 therapy (innate anti-PD-1 resistance, IPRES) (465). The possibility of 
combination therapy upregulating mechanisms of resistance pathways will need 
to be further explored in the MB49 model.  
Despite no clear synergistic benefit from combination therapy, and no 
definitive reasoning as to why combination treatment prolongs animal survival, I 
have hypothesized that addition of anti-PD-1 antibody may contribute to 
activation of regulatory immune function to subdue chronic inflammation adverse 
effects, which may improve survival. I have also suggested that “rescue” of fatty 
acid synthesis and metabolic gene expression by addition of andti-PD-1 mAb 
may contribute to the differences seen between combination treatment and 
poly(I:C) alone. Ingenuity Pathway Analysis (IPA) canonical pathway analysis 
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also shows that upregulated pathways are predominantly immune response 
related in poly(I:C) treatment, whereas combination treatment upregulates 
calcium signaling, G-protein signaling that regulates metabolic enzymes, ion 
channels, and transcriptional machinery, matrix metalloproteases, and wound 
healing pathways (actin cytoskeleton and intrinsic prothrombin activation 
pathways) in addition to immune response pathways and leukocyte extravasation 
signaling (Figure 20B). Combination treatment also more dramatically 
downregulates upstream regulator ACKR2, involved in regulating inflammatory 
cytokines. This combination of immune response, metabolic pathways, and ECM 
modification may be related to greater immune infiltration, or to promoting cancer 
growth and metastasis. Immune checkpoint inhibitors can regulate T cell 
migration, and particularly in the case of CTLA-4, can increase immune cell 
infiltration into tumors (and other tissues) (466). PD-L1 has been found to localize 
to the central T cell activation cluster and decrease antiviral CD8 T-cell motility; 
antibodies to PD-1 and PD-L1 restored CD8 T cell motility by limiting interaction 
time between T cells and DCs (467). While increasing motility, this effect of PD-1 
blockade becomes complicated as it reduces the efficacy of TCR signaling, 
raising the threshold needed for T cell activation (466). These analyses 
demonstrate that while not clearly synergistic, anti-PD-1 mAb in addition to IFN 
therapy may provide clinical benefit by increasing immune and TME regulatory 
functions that are not stimulated by IFN-I activation alone. Thus, though not 
synergistic in these studies, combination treatment of IFN and immune 
checkpoint blockade may provide improved therapeutic outcomes in NMIBC 
patients. 
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Chapter 5: Global Discussion (Implications) and Future Directions 
 
 Bladder cancer is a heterogeneous disease that affects a large proportion 
of cancer incidences, particularly in men, each year. Most patients are diagnosed 
with NMIBC, and though this classification of the disease is less severe and life-
threatening compared to MIBC, current standard treatment practices are not well-
defined, and result in 30-40% of patients exhibiting recurrent and progressive 
tumors (55, 69). Therefore, finding an effective alternative therapy that is 
mechanistically understood is essential to improve patient outcomes. Use of type 
I IFN and adenoviral-mediated IFN (Ad-IFN) have shown clinical response in 
this patient population, however i) its mechanisms of action have not been well 
characterized, and ii) IFN-I has been shown to increase tumor and TME immune-
evasion strategies such as upregulation of checkpoint markers, prompting the 
need to develop potential combination therapies. In this dissertation, I tested the 
hypothesis that immune-mediated mechanisms of type I IFN therapy with the 
general hypothesis that localized IFN-I treatment would increase immune cell 
recruitment and activation in tumors, creating an IFN driven antitumor response 
and an environment in which checkpoint blockade immunotherapy could 
counteract immune evasion and T cell exhaustion. In the course of these studies, 
I learned that local delivery of poly(I:C) and viral-mediated IFN incites 
inflammatory cytokines and chemokines, increases intratumoral effector immune 
cells, and inhibits tumor growth, prolonging survival. In characterizing this 
response, I found IL-6 had an important role in regulating positive responses to 
type I IFN therapy in both mice and humans, that IL-6 signaling was necessary 
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for antitumor effects of Ly6G cells and NK cell and T cell proliferation and 
activation. I further established that local delivery of poly(I:C) in combination with 
anti-PD-1 checkpoint modulator prolongs survival, which may be a product of 
anti-PD-1 mAb’s ability to regulate TME cell metabolism, and to reactivate 
regulatory cells to balance treatment efficacy and inflammatory pathology. I 
touched on how my findings supported or contradicted the current knowledge in 
the field, and speculated on the potential underlying mechanism for my results. In 
this chapter, I will discuss the potential future implications of my work, and 
address what areas of study need to be further pursued.  
IL-6 signaling has been portrayed as both promoting oncogenesis by 
supporting cancer cell proliferation, survival, and metastasis, and opposing tumor 
growth by mobilizing immune responses against the tumor. My findings outlined 
in Chapter 3 indicate that contrary to many publications categorizing high IL-6 
levels as a marker for poor prognosis and tumor progression, the induction of IL-
6 in mice and patients with bladder cancer treated with IFN therapy correlated 
with antitumor response and tumor regression. This implies that measureable IL-
6 levels may be used as a positive prognostic marker for IFN treatment of 
bladder cancer in the future. In this dissertation, I only touched on the need of IL-
6 in the poly(I:C) antitumor response, inhibiting tumor growth, promoting NK and 
T cell activation, and increasing intratumoral Ly6G+ cells, but further analysis of 
IL-6’s mechanisms of action would aid in understanding it’s defined role in the 
antitumor response for bladder cancer. IL-6 has been shown to inhibit Treg 
suppression of DC-mediated T cell activation (468), and promote Th17 cell 
differentiation, a process often connected by IL-6’s ability to suppress the Foxp3-
dependent Treg developmental program in favor of Th17 formation in the 
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presence of TGF (469). The effect of IL-6 on the CD4 T cell compartment in 
MB49 and other bladder cancer models needs to be further pursued as another 
effector mechanism of IFN-I. 
One of the areas brought into question from my studies was how 
combination treatment increased survival without having significantly smaller 
tumor sizes or greater expression of immune effector gene expression than 
poly(I:C) alone. To better elucidate the objective differences, if there are any, 
between poly(I:C) and combination poly(I:C) + anti-PD-1 therapy, the treatment 
dosing schedule may be an important area of future research. In this study, I 
treated mice concurrently with IFN agonist poly(I:C) and PD-1 inhibitor based on 
previously published work (375), however a delayed application of anti-PD-1, 
after IFN-I has been able to incite the inflammatory response (and upregulate 
PD-L1) may provide greater benefit. It has been shown that chemotherapy and 
radiation therapy given prior to checkpoint inhibition therapy generate antitumor 
and abscopal responses (470). As these therapies act to stimulate the antitumor 
response by increasing tumor antigenicity and immune cell activation, the same 
reasoning can be applied to innate immune stimulating therapy (IFN) being given 
prior to inhibitory checkpoint antagonists.  
Additionally, in the RNAseq data (Figure 19), I show that in comparison to 
poly(I:C), combination treated tumors have enriched expression of fatty acid 
metabolism. In Chapter 4, I mentioned that increasing mitochondrial FAO 
metabolism in T cells has been shown to favor the formation of long-lived 
memory T cells (462, 463), and FAO is necessary for other effector immune cell 
function: TLR-stimulated macrophages require increased FAO, and specifically 
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ACLY function, for cancer cell phagocytosis and antitumor activity (471). 
However, bladder cancer has been known to rely on glycolysis as well as fatty 
acid synthesis for oncogenesis (430, 431), and so, dual expression of fatty acid 
metabolism and glycolysis from the RNAseq analysis may indicate that the tumor 
itself is proliferating and may be a sign of tumor progression and therapeutic 
resistance.  
For the tumor to overcome an antitumor defense, it must co-opt the TME 
and induce its polarization to a more pro-tumor, immunosuppressive immune cell 
phenotype, thereby encouraging tumor growth and survival. Specific identification 
of which cells (immune subtypes or tumor) are exhibiting increased fatty acid 
metabolism (as well as glycolysis) is therefore an important next step in 
determining therapeutic strategies for bladder cancer. If the immune cells are 
exhibiting glycolysis and FAO metabolic signatures, this would signify an 
activated immune response capable of attacking tumors. If the tumor cells show 
increased glycolysis and FAO, this may be a sign of the Warburg effect, 
increased nucleotide, amino acid, and lipid biosynthesis, and ultimately tumor cell 
proliferation (472). To differentiate metabolic signatures between pro-tumor and 
anti-tumor immune cells, Liu and colleagues tested preferred utilization of TCA 
cycle intermediates for M2 pro-tumor macrophages and TLR-stimulated anti-
tumor macrophages. M2 macrophages preferred the use of exogenous fatty 
acids for TCA cycle components (and increased lipid transporter expression), 
whereas TLR stimulated macrophages showed preference for de novo lipid 
synthesis, displaying a shift away from complete utilization of carbon from 
glucose towards glutamine anaplerosis for generating TCA cycle components 
(471). A similar strategy can be employed to better understand the mixed 
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metabolic RNA profile seen in the treated MB49 tumors: investigation into ECAR, 
OCR, and lipid synthesis analysis of intratumoral immune cells and tumor cells 
will be important for identifying which cell components the metabolic changes are 
specifically attributed to and can help identify cells that are immunosuppressive, 
aiding in pinpointing targets for therapeutic intervention.  
 Combination treatment also showed enrichment of ECM and collagen 
modification gene expression, potentially hinting at increased cell motility or 
proliferation. Similar to the uncertain attribution of glycolysis and FAO metabolic 
genes, which cells contribute to this increased expression remains unclear. As 
previously stated, upregulation of expression of genes involved in ECM 
remodeling and mesenchymal transition has been shown to be a marker of tumor 
resistance to anti-PD-1 therapy in patients with metastatic melanoma (465). 
Further investigation into anti-PD-1 therapy resistance mechanisms in bladder 
cancer, and other cancers is an important field to pursue, and has only begun to 
be understood at the innate and adaptive cellular level (473).  It is not currently 
clear if the increased expression of cell motility and ECM modulation signaling is 
related to PD-1 resistance in the MB49 model. However, to investigate PD-1 
resistance as a possibility in IFN+anti-PD-1 treatment of bladder cancer, 
carcinogen-induced or transgenic murine models of bladder cancer may provide 
the best tumor genesis rate to test combination therapy resistance mechanisms, 
as MB49 tumors are fast-growing and may not provide sufficient time and 
opportunity to study. 
Looking to the future of bladder cancer treatment and considering my 
findings in this dissertation, I believe that efforts to inhibit IL-6 signaling, because 
of its role in chronic inflammation and potential relationship with tumor promotion, 
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are hasty (474). In models which require T cell priming for activation, IL6-/- mice 
display impaired involvement of innate cells (475). Likewise, inhibition of 
downstream IL-6-target STAT3, because of its role in regulating cell survival, 
proliferation, and angiogenesis (476), could negatively preclude the immune 
response due to STAT3 regulation of granulopoiesis, DC development and 
function, T cell differentiation and function, Treg development, and anti-
inflammatory signaling, among other effects (477). In this work, I show that IL-6 is 
a necessary component in the IFN-driven antitumor response. Immunotherapy, 
radiation therapy, and chemotherapy all rely on the immune response, including 
IFN signaling, to combat tumor growth; consequently, to some degree this will 
rely on inflammatory cytokines such as IL-6 to potentiate the antitumor immune 
response. Therefore, focus should be directed towards inciting the immune 
response in bladder cancer treatment, not inhibiting its effector branches. Ad-
IFN therapy theoretically reaches the goal of activating the immune response. 
The use of a viral vector delivery system can be difficult in cancer types that are 
systemic (blood), or those hard to reach without systemic administration 
(pancreatic, colon, lung, some prostate, etc.), exhibiting potential bystander 
events and adverse effects; this same reasoning makes viral-mediated therapy in 
bladder cancer more advantageous because of the ability to locally deliver the 
drug and avoid systemic toxicities. Because melanoma and other skin cancers 
are also easily accessible, Ad-IFN may be utilized in these indications as well.  
Despite the advantage of local delivery, treatment with Ad-IFN still shows 
less than 50% response rates in NMIBC patients (66, 67). This may be due to 
mixed ability of the drug to permeate through different patient’s urothelial barrier, 
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the heterogeneity of the bladder tumor landscape, upregulated immune evasion 
mechanisms, and inaccurately staged and stratified disease, as previously 
discussed. However, for BCG unresponsive patients, I think Ad-IFN is still a 
promising therapeutic alternative to cystectomy because it can sustain patient 
quality of life, and the contributing reasons for resistance to IFN therapy can be 
addressed by more vigilant clinical assessment and combination therapeutic 
approaches to target immune evasion strategies such as inhibitory checkpoints. 
To this end, PD-1 inhibition in combination with IFN therapy may not be 
the best therapeutic option when considering a more holistic immune therapy 
approach to bladder cancer. PD-1/PD-L1 pathway inhibition is effective at re-
stimulating exhausted T cells already in the tumor, whereas CTLA-4 inhibition 
has actually been shown to increase T cell activation and chemotaxis to tumors 
(294). The potential combination of anti-CTLA-4 mAb with viral-mediated IFN 
may prove to be more successful in inhibiting UC tumor growth though the 
enhanced recruitment of effector T cells, an additive effect to IFN-I’s diverse 
antitumor mechanisms. Anti-CTLA-4 therapy has been helpful to disease 
phenotypes with high mutational loads, due to more probable neoantigen targets 
for T cell attack (90); thus bladder cancer, having the third highest mutation 
landscape after melanoma and lung cancers (478), is a prime candidate for 
CTLA-4 targeted therapy.  Focusing more on therapies that are already approved 
for use in bladder cancer, and have shown efficacy, the combined use of IFN 
with BCG may be an attractive treatment strategy. Combination BCG + IFN2b 
was shown to potentiate the effects of BCG alone with a response rate of about 
60% in prior BCG failed patients (479). Because this study was performed with a 
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recombinant IFN protein, I would speculate that viral-mediated IFN would provide 
even greater clinical benefit due to its enhanced durability and permeation into 
the bladder wall.  
Together, my results provide a preclinical conceptual example for using 
type I IFN activation to increase the therapeutic benefit of PD-1 blockade for 
bladder cancer patients, as well as a rationale for pursuing further studies in 
NMIBC to optimize a treatment protocol (dosing and timing). Recent US Food 
and Drug Administration approval of atezolizumab (anti-PD-L1 mAb) and 
nivolumab (anti-PD-1 mAb) for treatment of metastatic urothelial carcinoma (63) 
has brought into question the role of immune therapy earlier in the treatment of 
UC, and thus clinical trials examining the effect of checkpoint inhibitors in earlier 
staged cancer is ongoing. To this point, Pietzak and colleagues showed that 
chemotherapeutic treatment of “secondary” MIBC, that is, tumors that have 
progressed to higher staged MIBC from previously diagnosed and treated 
NMIBC, had lower response rates and short survival compared to “primary” de 
novo, treatment naïve MIBC (480). Moving forward, I think the bladder cancer 
treatment field should focus on implementing a combination innate and adaptive 
stimulating immunotherapy strategy at earlier disease stages (not just BCG failed 
patients). It can broadly affect more patients rather than personalized targeted 
molecular therapies, and lead to better clinical outcomes for many subtypes of 
bladder cancer patients.   
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Chapter 6: Methodology 
 
Patient Samples 
 Patient specimens utilized in this study were collected from previous 
Phase I, Phase Ib, and Phase II clinical trials with adenoviral interferon-α2b 
formulated with Syn3 (Ad-IFNα/Syn3) with patient eligibility, treatment, and 
specimen collection approved by the University of Texas MD Anderson Cancer 
Center institutional review board (IRB) (66, 67, 408). 
 Urine samples utilized for preliminary marker identification (Figure 7) were 
collected for clinical research use from informed and consented patients about to 
undergo standard TURBT. Specimen collection was approved by the University 
of Texas MD Anderson Cancer Center IRB. 
 
Mice 
Wild-type male C57BL/6J mice, IL-6KO mice, RAG-/-, and p53 +/- mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). All gene-
deficient mice used are on the C57BL/6 background. IFNAR-/- (481) were 
provided by Dr. Paul W. Dempsey (Department Of Microbiology and Molecular 
Genetics, University of California, Los Angeles) and Dr. Tadatsugu Taniguchi 
(Department of Immunology, Tokyo University, Japan) to Dr. W. Overwijk and 
crossed to the C56BL/6 background. IL15Rα-/- mice (482) were originally 
generated by and obtained from Dr. Averil Ma through Dr. Leo Lefrancois and 
crossed to the C57BL/6 background.  All animal experiments were performed 
according to the institutional guidelines for the care and use of laboratory 
animals. 
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Cell Lines and Treatment in vitro 
MB49-GFP/luciferase murine bladder cancer cells were generously 
donated by Dr. Robert Svatek (the University of Texas Health San Antonio). Cells 
were grown in culture in modified Eagle medium containing 10% fetal bovine 
serum and 1% penicillin/streptomycin. MB49 bladder cancer cells were seeded in 
6-well plates and treated with 0-10,000 IU/mL recombinant murine IFNα (PBL 
Assay Science, Piscataway, NJ). After 24 hours of stimulation, cell death and 
apoptosis were analyzed by a combined PI/Annexin V (APC) assay (Invitrogen 
[Thermo Fisher Scientific], Carlsbad, CA), and analyzed by flow cytometry 
whereby early apoptosis (Annexin+PI-) and late apoptosis (Annexin+PI+) were 
quantified (n=2 biological replicates). UPPL1541 and UPPL1595 cell lines are 
established from a spontaneous primary bladder tumor in an Uroplakin-Cre 
driven PTEN/P53 knockout genetically engineered mouse model and were 
generously provided by Dr. William Kim (UNC Chapel Hill). 
 
Tumor Transplantation 
Mice were injected subcutaneously into the right flank with 1×105 MB49 
bladder cancer cells (1×106 or 1×107 for UPPL1595 and UPPL1541, 
respectively). For analysis of abscopal effect, following primary tumor injection of 
MB49 on right flank, a secondary tumor (1×105 MB49 cells) was injected in the 
left flank 4 days later. Tumor development was monitored by palpation and 
fluorescent imaging with the IVIS Spectrum In Vivo Imaging System and Living 
Image software (PerkinElmer, Waltham, MA). Mice were randomized into 
treatment groups on the basis of fluorescent intensity and palpated tumor size at 
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day 6 after implantation. From day 6 on, tumor size was measured every 3 days 
by caliper and was recorded as Area [L × W] in millimeters. Mice with tumors 
exceeding 20 mm in diameter or with large ulcerations were deemed moribund 
and euthanized. Each point on tumor growth graphs reflects the average area of 
the total starting number of mice per treatment group; graph lines are stopped 
when multiple mice in a group are euthanized. Experiments were performed in 
groups of five or more mice and repeated at least twice. 
 
Treatment of Mouse Tumors and Depletions 
When transplanted bladder tumors became palpable, poly(I:C) (100 µg; 
Invivogen, San Diego, CA) was injected peritumorally beginning on Day 6 or 7 
and continued every 3 days until mice were deemed moribund, or for tumor 
analysis after a total of 2, 3, or 4 treatments as denoted in Figure 8, 17. 
Therapeutic blockade of PD-1 was performed using rat anti-mouse PD-1 mAb 
(200 µg, i.p., clone RMP1-14; BioXcell, West Lebanon, NH) or control-rat IgG 
mAb (200 µg, i.p.; Jackson ImmunoResearch Laboratories Inc., West Grove, PA) 
every 3 days in conjunction with poly(I:C) treatment. Antibody-mediated depletion 
of T cells or natural killer cells was induced with rat anti-mouse Thy1.2 mAB (300 
µg, i.p. clone 30H12; BioXcell), rat anti-mouse CD8 mAb (300µg, i.p. clone 2.43; 
BioXcell), or rat anti-mouse Nk1.1 mAb (300µg, i.p. clone PH136; BioXcell) 
delivered two times, 1 week apart. Ly6G and CSFR1 mAbs (400µg, i.p. clones 
1A8 and AFS98 respectively; BioXcell) were given three times a week until 
mouse morbidity. Greater than 85% depletions of target cells were confirmed by 
flow cytometry of peripheral blood samples taken 1-2 days after Ab treatment. 
Efficiency of cell depletions is represented in Figure 21. All treatments and  
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Figure 21: Efficacy of Immune cell subset depletions. A) mAb depletion of 
Ly6G+ cells; flow plot is of gated lineage-(TCRβ-CD19-NK1.1-)CD11b+ cells. B) 
mAb depletion of CD8 T cells; flow plot is of gated TCRβ+ cells. C) mAb depletion 
of NK cells; flow plot is of gated TCRβ- cells. D) mAb depletion of all T cell 
subsets by Thy1.2 antibody. All samples from peripheral blood. Plots are 
representative of n=5. 
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depletions were performed in Wild-type male C57BL/6J mice, male IL-6KO mice 
(B6.129S2-Il6tm1Kopf/J), and male RAG-/- (B6.129S7-Rag1tm1Mom/J) mice (The 
Jackson Laboratory; Bar Harbor, ME). 
 p53+/- mice (8 weeks old) were treated with 0.25% N-butyl-N-(4-
hydroxybutyl) nitrosamine (BBN) in drinking water for 12 weeks (483). By 16 
weeks mice develop carcinoma-in-situ (CIS) which proceeded to invasive cancer 
by 30 weeks. Mice were treated with LV Ctrl or LV IFN (3X107 virus particles) for 
4 weeks starting at 16 weeks of age (Lentiviral Vectors [LV-Control and LV-IFN] 
provided by FKD Therapies, University of Finland). Excipient SYN3 (1mg/ml) was 
used as vehicle for all treatment. For intravesical treatment, mice were 
anesthetized and mouse urethra was catheterized with 20G angiocatheter and 
after emptying the bladder contents, virus was instilled (100 μl) volume and 
allowed to dwell in the bladder for 40 mins. After instillation of virus, mice were 
allowed to recover and returned to their cages. 
 
T cell Stimulation 
For intracellular cytokine and IFNγ staining, MB49 tumor-infiltrating 
immune cells were isolated by manual homogenization followed by Percoll 
gradient, and plated into 6-well plates coated with anti-CD3 antibody, incubated 
in RPMI with 10% fetal bovine serum with protein transport inhibitors GolgiStop 
and GolgiPlug (2 µg/mL; BD Biosciences, San Jose, CA) for 5 hours (n=4). After 
incubation, cells were stained for surface markers and then fixed and 
permeabilized prior to staining for intracellular proteins.  
 
Murine Cytokine Analysis 
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 Murine cytokines were measured by ELISA: IFNα (PBL VeriKine Mouse 
Interferon Alpha ELISA kit, 42120-1; Piscataway, NJ) and IL-6 (R&D Mouse IL-6 
Quantikine ELISA Kit, M6000B; Minneapolis, MN). Samples were run in duplicate 
and ELISA was performed according to manufacturer instructions. Plates were 
read on Molecular Devices Spectra Max Plus384 plate reader. 
 
Immunohistochemistry and Immunofluorescence Staining 
Mouse tumors were fixed in 10% phosphate-buffered formalin, embedded 
in paraffin, and sectioned by the Research Histology Core Laboratory at The 
University of Texas MD Anderson Cancer Center. Patient tumors were isolated 
and processed according to the phase I trial protocol (66, 408) and obtained from 
MD Anderson. Immunohistochemistry was performed with either rat anti-mouse 
CD31 mAb (SZ31, Dianova, Hamburg, Germany) or rabbit anti-human CD3 pAb 
(A0452, Dako [Agilent], Santa Clara, CA) followed by rabbit-anti rat HRP- or 
goat-anti rabbit HRP–conjugated secondary antibody respectively (Bio-rad 
Laboratories, Hercules, CA) and the DAB peroxidase substrate kit (Vector 
Laboratories, Inc. Burlingame, CA). Sections were then counterstained with 
hematoxylin. Tissue sections were blindly quantified by manual counting. 
Representative areas (2-3) from each CD31 stained section (n=12 in total) with 
most intensive microvessel density was captured under the light microscope at 
200x (Leica). MVD per tumor section was calculated from the average count of 
CD31+ vessels per representative area, averaging total number from n=3 tumors 
per treatment group. Total image length is 384µm. Immunofluorescence was 
performed using rat mAb CD4 (GK1.5, Abcam, Cambridge, MA) and rabbit pAb 
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CD8 antibodies (ab4055, Abcam). Sections were examined with a Nikon 
microscope and camera and processed in ImageJ. 
 
Flow Cytometry 
Tumor-infiltrating immune cells were isolated by manual homogenization 
and digestion of tumors or bladders (BBN-induced), followed by Percoll gradient, 
and stained with fluorochrome-conjugated mAbs specific for mouse surface 
markers CD45, CD44, CD8, CD4, Nk1.1, CD11b, CD11c, Ly6C, Ly6G, CD19, 
TCRβ, F4/80 (BD Biosciences, Ebioscience/Thermo Fisher Scientific) according 
to standard procedures. Intracellular staining (T cell Stimulation) for IFNγ, and 
Ki-67 and granzyme-B was performed after permeabilization of cell membranes 
using the Transcription Factor Staining Buffer Set from eBioscience 
(ThermoFisher).  
Human urine samples were collected and stained for immune and 
epithelial markers for flow cytometry. Briefly, samples were centrifuged at 2000 
RPM, washed with DPBS, and centrifuged at 2000 RPM again. Pellets were 
resuspended in 1mL of DPBS, counted on hemocytometer, and aliquoted to a 
maximum of 106 cells per tube. Samples were then stained with fluorochrome-
conjugated mAbs specific for human markers CD45, cytokeratin, CD8, TCR, 
PD-1, PD-L1 (Thermo Fisher Scientific) according to standard procedures. 
All samples were run on a BD LSRFortessa unit and analyzed by FlowJoX 
software (Flowjo LLC, Ashland, OR). 
 
Reverse Transcriptase PCR 
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Tumor samples were harvested and immediately snap-frozen in liquid 
nitrogen. Total RNA was isolated using the mirVana miRNA isolation kit with 
phenol (Ambion [Thermo Fischer Scientific], Carlsbad, CA) with concentration 
measured on the NanoDrop ND-1000 Spectrophotometer. One-step quantitative 
reverse transcriptase PCR was performed with diluted RNA, AgPath-ID One-step 
reverse transcriptase PCR reagents, and Taqman gene expression assay 
primers (Thermo Fisher Scientific) for the genes indicated, using relative 
expression of GAPDH as a reference gene. Samples were analyzed on the 
StepOnePlus Real-Time PCR System with StepOne Software v2.3 (Applied 
Biosystems [Thermo Fisher Scientific]). 
 
RNA-seq of Murine Tumors 
Stranded Total RNA sequencing was performed by the MD Anderson 
Sequencing and Microarray Facility (SMF) on the Illumina Hi-Seq 4000 platform. 
RNA samples were isolated from MB49 tumors using the mirVana miRNA 
isolation kit with phenol (Ambion [Thermo Fisher Scientific]), confirmed purity and 
concentration by the Agilent 2100 Bioanalyzer (Agilent Technologies [Thermo 
Fisher Scientific]) and Nanodrop ND-1000 Spectrophotometer, and sent to SMF. 
Raw reads in FASTQ format were aligned to the mouse reference genome, 
GRCm38/mm10, using MOSAIK alignment software. Mapped reads were used to 
generate raw counts for each gene using HTSeq. Counts data were normalized 
across samples with DESeq (484) and normalized expression values were 
analyzed by Morpheus matrix visualization and analysis software (Broad 
Institute), Gene Set Enrichment Analysis (GSEA) software (Broad Institute), and 
Ingenuity Pathway Analysis (IPA) software (Qiagen). The up-regulated pathways 
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in GSEA were defined by a normalized enrichment score (NES) >0. Only the top 
20 pathways more enriched in each treatment group were listed. 
 
Urinary Cytokine Analysis 
Frozen patient urines collected from baseline Day 1 (D1) pre-treatment, 
and Day 4 and Day 12 (D4, D12) post treatment of Phase I and II clinical trials 
with Instiladrin (Ad-IFNα/Syn3) by the SUOCTC working group were thawed and 
diluted before analysis with the Bio-Plex ProTM Cytokine, Chemokine, and Growth 
Factor Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA). We utilized antibody 
targets from the Human Cytokine Standard Groups I and II. Samples were run in 
duplicate and the plate was read with Bio-Plex ManagerTM software (Bio-Rad 
Laboratories, Inc) in the MD Anderson Department of Surgery. Observed 
concentration was log2 transformed, and graphed with baseline corrected to Day 
1 levels of each cytokine. Patients with undetectable levels of cytokines were left 
out of analyses. Assessment: of the 39 total patients, 13 were deemed as 
“responders” (CR) as defined by no evidence of recurrence of a high grade tumor 
by cystoscopy, cytology, or if clinically indicated, biopsy at 12 months. The other 
26 patients were deemed “non-responders” (NR). Correlation between IFNa2 
levels and other cytokines were deemed as moderately positive if r > 0.5 and 
strongly positive if r >0.7. Positive correlation was considered statistically 
significant if p value <0.05. 
 
Analyses of Gene Expression for Patients Treated with Ad-IFNα 
RNA isolation  
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The tumor areas in formalin fixed, paraffin-embedded (FFPE) human 
specimens from the Phase I, Ib, and II trials with Instiladrin (Ad-IFNα/Syn3) were 
reviewed by a genitourinary pathologist.  Total RNA from 8 matched (16 total) 
FFPE tumors was isolated using the High Pure miRNA isolation kit (Roche, 
Indianapolis, IN) according to the manufacturer’s instructions. Briefly, for the 
deparaffinization, five to ten (depending on the tumor area) 10 µm sections were 
incubated with xylene for 5 minutes, followed by two ethanol washes and dried 
for 10 minutes at 55°C. The dried tissues were incubated with proteinase K for 3 
hours at 55°C degree, followed by two washes according to the instructions of 
the manufacturer. RNA was eluted with water and treated with DNAse for 30 
mins at 37°C. DNAse treated RNA was washed twice according to the with 
manufacturer’s instructions and eluted with water. RNA purity and integrity was 
measured by NanoDrop ND-1000 and Agilent 2100 Bioanalyzer and only high 
quality RNA was used for library preparation. 
Library preparation and sequencing 
Whole transcriptome RNA sequencing was performed using Ion Torrent’s 
AmpliseqRNA platform (Thermo Fisher Scientific) and an Ion Proton sequencer 
(Thermo Fisher Scientific). Twenty nanograms of purified RNA was transcribed 
into cDNA using the SuperScript® VILO™ kit. Then cDNA was amplified using 
the Ion Ampliseq Transcriptome Human Gene Expression Core panel, followed 
by ligation of adapters and barcodes to amplicons and purification. Purified 
libraries were quantified using the Ion Library Quantification kit (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Libraries were diluted to 
100 pM and pooled in sets of 8. Pooled libraries were amplified on Ion SphereTM 
particles (ISP) using emulsion PCR and enriched on the IonChef (Thermo Fisher 
 143 
Scientific). Template positive ISPs were loaded into Ion PI chips and run on the 
Proton instrument in the Genomics Core in the Department of Urology at The 
University of Texas MD Anderson Cancer Center. 
Bioinformatics Analysis 
RNA-Seq gene expression analysis: Primary analysis of RNA sequencing 
data was performed using AmpliSeqRNA analysis plugin in the Torrent Suite 
Software. This plugin aligned the raw sequence reads to a human reference 
genome that contains 20,802 RefSeq transcripts (hg19 Ampliseq 
Transcriptome_ERCC_V1.fasta) using the Torrent Mapping Alignment Program 
(TMAP). Then, the number of reads mapped per gene will be counted to 
generate raw counts files and normalized reads per gene per million mapped 
reads (RPM) files. To visualize expression patterns, log ratios of POST/PRE 
gene expression of matched tumors were used for hierarchical clustering with 
Cluster and TreeView (485), or log2 normalized expression values were analyzed 
by Morpheus matrix visualization and analysis software (Broad Institute). 
Assessment: of the 8 total patients analyzed, none were classified as 
“responders” (CR) as defined by no evidence of recurrence of a high grade tumor 
by cystoscopy, cytology, or if clinically indicated, biopsy at 12 months. 
 
Statistical Analyses 
Statistical analyses of experimental results were evaluated with the 
GraphPad Prism 7 software. Two-tailed Student t tests, log-rank analyses, or 
multiple unpaired t tests were performed using averaged treatment group 
measurements at any one time point, as indicated. One way ANOVA with 
multiple comparisons was used for patient urine samples for each cytokine. 
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Results were considered statistically significant when *, P < 0.05; ** P <0.01; *** 
P<0.001. 
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